WO2013170970A1 - Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam - Google Patents

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam Download PDF

Info

Publication number
WO2013170970A1
WO2013170970A1 PCT/EP2013/001469 EP2013001469W WO2013170970A1 WO 2013170970 A1 WO2013170970 A1 WO 2013170970A1 EP 2013001469 W EP2013001469 W EP 2013001469W WO 2013170970 A1 WO2013170970 A1 WO 2013170970A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pharmacologically active
dosage form
pharmaceutical dosage
range
Prior art date
Application number
PCT/EP2013/001469
Other languages
French (fr)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2873863A priority Critical patent/CA2873863A1/en
Priority to SI201330919T priority patent/SI2849746T1/en
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Priority to NO13724168A priority patent/NO2849746T3/no
Priority to LTEP13724168.3T priority patent/LT2849746T/en
Priority to EP13724168.3A priority patent/EP2849746B1/en
Priority to EA201401265A priority patent/EA026719B1/en
Priority to CN201380025679.3A priority patent/CN104302288A/en
Priority to BR112014028569A priority patent/BR112014028569A2/en
Priority to RS20180128A priority patent/RS56830B1/en
Priority to JP2015511956A priority patent/JP6116677B2/en
Priority to AU2013262076A priority patent/AU2013262076B2/en
Priority to ES13724168.3T priority patent/ES2659948T3/en
Priority to MX2014012862A priority patent/MX354685B/en
Priority to PL13724168T priority patent/PL2849746T3/en
Priority to DK13724168.3T priority patent/DK2849746T3/en
Publication of WO2013170970A1 publication Critical patent/WO2013170970A1/en
Priority to IL235652A priority patent/IL235652B/en
Priority to HK15105570.0A priority patent/HK1204939A1/en
Priority to HRP20171843TT priority patent/HRP20171843T1/en
Priority to CY20181100090T priority patent/CY1119824T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • composition comprising (1 r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'- dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro- 3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
  • a first pharmacologically active ingredient which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro- 3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b
  • Oxicams are enolic acids which may preferably be regarded as NSAIDs, i.e. non-steroidal anti-inflammatory and antirheumatic drugs, which have anti-inflammatory, analgesic and antipyretic activity.
  • NSAIDs i.e. non-steroidal anti-inflammatory and antirheumatic drugs, which have anti-inflammatory, analgesic and antipyretic activity.
  • two pharmacologically active compounds exerting a synergistic effect may be combined in one single pharmaceutical dosage form, e.g. a tablet, thus enhancing patient compliance.
  • compositions which have advantages compared to pharmaceutical compositions of the prior art.
  • the pharmaceutical compositions should provide rapid therapeutic effects, but also should have a high tolerability, good compliance and safety.
  • a pharmaceutical composition comprising (1r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine and an oxicam is useful for the treatment of pain, especially chronic inflammatory pain, or acute or non-chronic postoperative (postsurgical) pain.
  • composition exhibits a synergistic therapeutic effect upon administration. Therefore, the overall administered dose may be lowered, so that fewer undesired side-effects will occur.
  • a first aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: a) a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N- dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 , 1 '-pyrano[3,4,b]indol]-4- amine and the physiologically acceptable salts thereof, and b) a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
  • the pharmaceutical composition according to the invention comprises a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl- 4',9'-dihydro-3'l-l-spiro[cyclohexane-1 > 1 '-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof.
  • (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l- spiro[cyclohexane-1 ,1'-pyrano [3,4,b]indol]-4-amine is the compound according to formula (I) which can also be referred to as 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro- 1 ,3,4,9-tetrahydropyrano[3,4-b]indole (trans)
  • the definition of the first pharmacologically active ingredient includes (1r,4r)-6'-fluoro-N,N- dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 , 1 '-pyrano-[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I), in any possible form including solvates, cocrystals and polymorphs, and its physiologically acceptable salts, in particular acid addition salts and corresponding solvates, cocrystals and polymorphs.
  • the pharmacologically active ingredient (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro- 3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine may be present in the pharmaceutical composition according to the invention in form of a physiologically acceptable salt, preferably an acid addition salt, whereby any suitable acid capable of forming such an addition salt may be used.
  • Suitable acids include but are not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid.
  • Salt formation is preferably effected in a solvent, for example, diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or 2-butanone.
  • trimethylchlorosilane in aqueous solution is also suitable for the preparation of hydrochlorides.
  • the first pharmacologically active ingredient is (1 r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I).
  • the first pharmacologically active ingredient is (1 r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4- amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt.
  • the pharmaceutical composition according to the invention comprises a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
  • a second pharmacologically active ingredient which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
  • Meloxicam, piroxicam, tenoxicam, lornoxicam and droxicam are the compounds according to formulas (II), (III), (IV), (V) and (VI), respectively.
  • the definition of the second pharmacologically active ingredient includes the aforementioned oxicams in any possible form including any enantiomers, if applicable, solvates, prodrugs, cocrystals and polymorphs, and their physiologically acceptable salts, in particular metal and ammonium salts and corresponding solvates, cocrystals and polymorphs.
  • the preferred oxicams according to any of formulas (II) to (VI) are devoid of an acid functionality as such, they bear acidic protons since they exhibit a keto-enol tautomerism. Additionally, they may contain nitrogen functionalities. Thus, the conversion into a salt may be effected in a manner well known to those skilled in the art, for example, via reaction with a suitable base, but as well with an acid or metal salt.
  • Suitable bases include but are not limited to inorganic bases, including the hydroxides of sodium, potassium, calcium and/or magnesium, and organic bases, such as triethyl amine, trimethylamine, N,N-diisopropyl- ethylamine, N-methylmorpholine, N-methylpiperidine and ammonia.
  • Suitable acids include but are not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid.
  • trimethylchlorosilane in aqueous solution is also suitable for the preparation of hydrochlorides.
  • Suitable metal salts include but are not limited to alkali salts such as sodium, potassium or lithium phosphate, sulfate, methanesulfonate, formate, acetate, oxalate, succinate, tartrate, mandelate, fumarate, lactate, citrate, glutamate, aspartate and/or silyls, as well as alkaline earth salts, in particular magnesium and calcium salts, including their phosphate, sulfate, methanesulfonate, formate, acetate, oxalate, succinate, tartrate, mandelate, fumarate, lactate, citrate, glutamate, aspartate and/or silyl salts.
  • Salt formation is preferably effected in a solvent, for example, diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or
  • ethers and esters are especially preferred.
  • Suitable methods for selecting and preparing a prodrug of a given substance are, for example, described in "Textbook of Drug Design and Discovery", 3 rd edition, 2002, chapter 14, pages 410-458, Editors: Krogsgaard-Larsen et al., Taylor and Francis.
  • the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
  • the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam and the physiologically acceptable salts thereof.
  • the second pharmacologically active ingredient is an oxicam in form of the free compound, i.e. according to any of formulas (II) to (VI).
  • the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the free compound, i.e. according to any of formulas (II) to (V).
  • the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the respective sodium salt.
  • the second pharmacologically active ingredient is meloxicam.
  • the first pharmacologically active ingredient is (1r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam according to any of formulas (II) to (VI).
  • the first pharmacologically active ingredient is (1r,4r)-6 - fluoro-N.N-dimethyl ⁇ -phenyl ⁇ ' ⁇ '-dihydro-S'H-spirofcyclohexane-I '-pyranoIS ⁇ .blindolH- amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam according to any of formulas (II) to (V).
  • the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]- 4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the respective sodium salt.
  • the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]- 4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is meloxicam according to formula (II).
  • the first pharmacologically active ingredient is (1r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4- amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt, and the second pharmacologically active ingredient is meloxicam according to formula (II).
  • the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]- 4-amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt, and the second pharmacologically active ingredient is meloxicam in form of the sodium salt.
  • the second pharmacologically active ingredient bears an acidic proton due to a keto- enol tautomerism, it may react with the first pharmacologically active ingredient according to formula (I) forming a salt which incorporates both pharmacologically active ingredients.
  • the pharmaceutical composition according to the invention comprises the first and the second pharmacologically active ingredient in form of a salt formed from these two pharmacologically active ingredients.
  • a salt formation may be partial, i.e. the pharmaceutical composition according to the invention comprises one or both of these pharmacologically active ingredients also in their non-salt form, or the salt formation may essentially be complete.
  • Another aspect of the invention relates to a pharmaceutical dosage form comprising the pharmaceutical composition according to the invention.
  • the first and the second pharmacologically active ingredient are typically contained in the pharmaceutical dosage form according to the invention in a therapeutically effective amount.
  • the amount that constitutes a therapeutically effective amount varies according to the pharmacologically active ingredients, the condition being treated, the severity of said condition, the patient being treated, and whether the pharmaceutical dosage form is designed for an immediate or controlled release.
  • the content of the first pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at most 10 wt.-% or at most 5 wt.-% or at most 3 wt.-% or at most 1.0 wt.-%, more preferably at most 0.8 wt.-%, yet more preferably at most 0.5 wt.-%, still more preferably at most 0.2 wt.-%, even more preferably at most 0.1 wt.-%, most preferably at most 0.05 wt.-%, and in particular at most 0.01 wt.-% or at most 0.005 wt- % or at most 0.001 wt.-%.
  • the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at most 95 wt.-%, more preferably at most 80 wt.-%, yet more preferably at most 70 wt.-%, still more preferably at most 60 wt.-%, even more preferably at most 55 wt.-%, most preferably at most 50 wt.-%, and in particular at most 45 wt.-%.
  • the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively is at most 45 wt.-%, more preferably at most 30 wt.-%, yet more preferably at most 20 wt.-%, still more preferably at most 15 wt.-%, even more preferably at most 10 wt.-%, most preferably at most 5 wt.-%, and in particular at most 1 wt.-%.
  • the content of the first pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at least 0.0001 wt.-%, more preferably at least 0.0003 wt.-%, yet more preferably at least 0.0005 wt.-%, still more preferably at least 0.0008 wt.-%, even more preferably at least 0.001 wt.-%, most preferably at least 0.003 wt.-%, and in particular at least 0.005 wt.-%.
  • the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at least 0.1 wt.-%, more preferably at least 0.5 wt.-%, yet more preferably at least 1 wt.-%, still more preferably at least 3 wt.-%, even more preferably at least 5 wt.-%, most preferably at least 7.5 wt.-%, and in particular at least 10 wt.-%.
  • the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively is at least 0.01 wt.-%, more preferably at least 0.02 wt.-%, yet more preferably at least 0.04 wt.-%, yet more preferably at least 0.06 wt.-%, most preferably at least 0.08 wt.-%, and in particular at least 0.1 wt.-%.
  • wt.-% shall mean weight of the respective ingredient per total weight of the pharmaceutical dosage form or per total weight of the pharmaceutical composition, respectively.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, more preferably 1 : 2 to 1 : 10,000, and most preferably 1 : 5 to 1 : 5,000.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 100, more preferably 1 : 4 to 1 : 90, still more preferably 1 : 6 to 1 : 80, most preferably 1 : 7 to 1 : 70, and in particular 1 : 10 to 1 : 60.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 20 to 1 : 200, more preferably 1 : 30 to 1 : 185, still more preferably 1 : 50 to 1 : 170, yet more preferably 1 : 60 to 1 : 160, most preferably 1 : 70 to 1 : 140, and in particular 1 : 80 to 1 : 120.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 100 to 1 : 900, more preferably 1 : 250 to 1 : 800, still more preferably 1 : 300 to 1 : 700, most preferably 1 : 350 to 1 : 650, and in particular 1 : 400 to 1 : 600.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 500 to 1 : 5,000, more preferably 1 : 600 to 1 : 4,000, still more preferably 1 : 700 to 1 : 3,000, most preferably 1 : 750 to 1 : 2,500, and in particular : 800 to 1 : 2,000.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 1 ,000 to 1 : 9,000, more preferably 1 : 2,500 to 1 : 8,000, still more preferably 1 : 3,000 to 1 : 7,000, most preferably 1 : 3,500 to 1 : 6,500, and in particular 1 : 4,000 to 1 : 6,000.
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 3,000 to 1 : 10,000, more preferably 1 : 4,000 to 1 : 9,800, still more preferably 1 : 5,000 to 1 : 9,600, most preferably 1 : 6,000 to 1 : 9,500, and in particular 1 : 7,000 to 1 : 9,000.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, more preferably 1 : 2 to 1 : 10,000, and most preferably 1 : 5 to 1 : 5,000.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 100, more preferably 1 : 4 to 1 : 90, still more preferably 1 : 6 to 1 : 80, most preferably 1 : 7 to 1 : 70, and in particular 1 : 10 to 1 : 60.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 20 to 1 : 200, more preferably 1 : 30 to 1 : 185, still more preferably 1 : 50 to 1 : 170, yet more preferably 1 : 60 to 1 : 160, most preferably 1 : 70 to 1 : 140, and in particular 1 : 80 to 1 : 120.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 100 to 1 : 900, more preferably 1 : 250 to 1 : 800, still more preferably 1 : 300 to 1 : 700, most preferably 1 : 350 to 1 : 650, and in particular 1 : 400 to 1 : 600.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 500 to 1 : 5,000, more preferably 1 : 600 to 1 : 4,000, still more preferably 1 : 700 to 1 : 3,000, most preferably 1 : 750 to 1 : 2,500, and in particular 1 : 800 to 1 : 2,000.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 1 ,000 to 1 : 9,000, more preferably 1 : 2,500 to 1 : 8,000, still more preferably 1 : 3,000 to 1 : 7,000, most preferably 1 : 3,500 to 1 : 6,500, and in particular 1 : 4,000 to 1 : 6,000.
  • the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 3,000 to 1 : 10,000, more preferably 1 : 4,000 to 1 : 9,800, still more preferably 1 : 5,000 to 1 : 9,600, most preferably 1 : 6,000 to 1 : 9,500, and in particular 1 : 7,000 to 1 : 9,000.
  • the amounts of the first and the second pharmacologically active ingredient contained in the pharmaceutical dosage form according to the invention may vary depending on different factors well known to those skilled in the art, for example, the weight of the patient, the route of administration, the severity of the illness and the like.
  • both pharmacologically active ingredients contained in the pharmaceutical dosage form according to the invention may be administered in amounts up to their maximum daily dose, which is known to those skilled in the art.
  • meloxicam may preferably be administered to a patient in a maximum daily dose of up to 15 mg
  • piroxicam may preferably be administered to a patient in a maximum daily dose of up to 40 mg
  • tenoxicam may preferably be administered to a patient in a maximum daily dose of up to 40 mg
  • lornoxicam may preferably be administered to a patient in a maximum daily dose of up to 16 mg.
  • the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention preferably contain the first and the second pharmacologically active ingredient, independently of one another, in an amount corresponding to 75 ⁇ 15 wt.-%, 75 ⁇ 10 wt.-%, 75 ⁇ 5 wt.-%, 50 ⁇ 15 wt.-%, 50 ⁇ 10 wt.-%, 50 ⁇ 5 wt.-%, 25 ⁇ 5 wt.-%, 25 ⁇ 10 wt.-% or 25 ⁇ 5 wt.-% of the respective maximum daily dose of the first and the second pharmacologically active ingredient, respectively.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose of from 0.1 pg to 5,000 pg, more preferably, 0.1 pg to 2,500 pg, still more preferably 1.0 pg to 1 ,000 pg, yet more preferably 10 to 800 pg, most preferably 15 pg to 600 pg, and in particular 20 pg to 440 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 13 ⁇ 12 pg, more preferably 13 ⁇ 10 pg, still more preferably 13 ⁇ 8 pg, yet more preferably 13 ⁇ 6 pg, even more preferably 13 ⁇ 5 pg, most preferably 13 ⁇ 4 pg, and in particular 13 ⁇ 3 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 20 ⁇ 15 pg, more preferably 20 ⁇ 13 pg, still more preferably 20 ⁇ 12 pg, yet more preferably 20 ⁇ 10 pg, even more preferably 20 ⁇ 8 pg, most preferably 20 ⁇ 6 pg, and in particular 20 ⁇ 5 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 40 ⁇ 35 pg, more preferably 40 ⁇ 30 pg, still more preferably 40 ⁇ 25 pg, yet more preferably 40 ⁇ 20 g, even more preferably 40 ⁇ 15 ⁇ g, most preferably 40 ⁇ 10 pg, and in particular 40 ⁇ 5 M9-
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 60+50 pg, more preferably 60 ⁇ 40 pg, still more preferably 60 ⁇ 30 pg, yet more preferably 60 ⁇ 20 pg, most preferably 60 ⁇ 10 pg, and in particular 60 ⁇ 5 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 80 ⁇ 70 pg, more preferably 80 ⁇ 60 pg, still more preferably 80 ⁇ 50 pg, yet more preferably 80 ⁇ 40 pg, even more preferably 80 ⁇ 20 pg, most preferably 80 ⁇ 10 pg, and in particular 80 ⁇ 5 M9-
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 100 ⁇ 90 pg, more preferably 100 ⁇ 80 pg, still more preferably 100 ⁇ 60 pg, yet more preferably 100 ⁇ 40 pg, even more preferably 100 ⁇ 20 pg, most preferably 100 ⁇ 10 pg, and in particular 100 ⁇ 5 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 120 ⁇ 100 pg, more preferably 120 ⁇ 80 pg, still more preferably 120 ⁇ 60 pg, yet more preferably 120 ⁇ 40 pg, even more preferably 120 ⁇ 20 pg, most preferably 120 ⁇ 10 pg, and in particular 120 ⁇ 5 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 150 ⁇ 90 pg, more preferably 150 ⁇ 80 pg, still more preferably 150 ⁇ 60 pg, yet more preferably 150 ⁇ 40 pg, even more preferably 150 ⁇ 20 pg, most preferably 150 ⁇ 10 pg, and in particular 150 ⁇ 5 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 170 ⁇ 130 pg, more preferably 170 ⁇ 100 pg, still more preferably 170+80 pg, yet more preferably 170 ⁇ 60 pg, even more preferably 170 ⁇ 40 pg, most preferably 170 ⁇ 20 pg, and in particular 170 ⁇ 10 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 200 ⁇ 175 pg, more preferably 200 ⁇ 150 pg, still more preferably 200 ⁇ 125 pg, yet more preferably 200 ⁇ 100 pg, even more preferably 200+75 pg, most preferably 200 ⁇ 50 pg, and in particular 200 ⁇ 25 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 400 ⁇ 350 pg, more preferably 400 ⁇ 300 pg, still more preferably 400 ⁇ 250 pg, yet more preferably 400 ⁇ 200 pg, even more preferably 400 ⁇ 150 pg, most preferably 400 ⁇ 100 pg, and in particular 400 ⁇ 50 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 600 ⁇ 400 pg, more preferably 600 ⁇ 300 pg, still more preferably 600 ⁇ 250 pg, yet more preferably 600 ⁇ 200 pg, even more preferably 600 ⁇ 150 pg, most preferably 600 ⁇ 100 pg, and in particular 600 ⁇ 50 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 800 ⁇ 550 pg, more preferably 800+400 pg, still more preferably 800 ⁇ 350 pg, yet more preferably 800 ⁇ 250 pg, even more preferably 800 ⁇ 150 pg, most preferably 800 ⁇ 100 pg, and in particular 800 ⁇ 50 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 1 ,000 ⁇ 800 pg, more preferably 1 ,000 ⁇ 600 pg, still more preferably 1 ,000 ⁇ 500 pg, yet more preferably 1 ,000 ⁇ 300 pg, even more preferably 1 ,000 ⁇ 200 pg, most preferably 1 ,000 ⁇ 100 pg, and in particular 1 ,000 ⁇ 50 pg.
  • the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 1 ,200 ⁇ 1 ,000 pg, more preferably 1 ,200 ⁇ 800 pg, still more preferably 1 ,200 ⁇ 600 pg, yet more preferably 1 ,200 ⁇ 400 [ig, even more preferably 1 ,200 ⁇ 200 pg, most preferably 1 ,200 ⁇ 100 ig, and in particular 1 ,200 ⁇ 50 [ig.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose of from 1 mg to 75 mg, more preferably, 2 mg to 60 mg, still more preferably 5 mg to 50 mg, most preferably 8 mg to 40 mg, and in particular 10 mg to 30 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 10 ⁇ 8 mg, more preferably 10 ⁇ 6 mg, most preferably 10 ⁇ 4 mg, and in particular 10 ⁇ 2 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 15 ⁇ 10 mg, more preferably 15 ⁇ 8 mg, still more preferably 15 ⁇ 6 mg, most preferably 15 ⁇ 4 mg, and in particular 15 ⁇ 2 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 20 ⁇ 15 mg, more preferably 20 ⁇ 14 mg, still more preferably 20 ⁇ 12 mg, yet more preferably 20 ⁇ 10 mg, most preferably 20 ⁇ 8 mg, and in particular 20 ⁇ 5 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 25 ⁇ 15 mg, more preferably 25 ⁇ 14 mg, still more preferably 25 ⁇ 13 mg, yet more preferably 25 ⁇ 12 mg, most preferably 25 ⁇ 10 mg, and in particular 25 ⁇ 7 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 30 ⁇ 20 mg, more preferably 30 ⁇ 18 mg, still more preferably 30 ⁇ 15 mg, yet more preferably 30 ⁇ 13 mg, most preferably 30 ⁇ 10 mg, and in particular 30 ⁇ 8 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 35 ⁇ 20 mg, more preferably 35 ⁇ 18 mg, still more preferably 35 ⁇ 15 mg, yet more preferably 35 ⁇ 13 mg, most preferably 35 ⁇ 10 mg, and in particular 35 ⁇ 8 mg.
  • the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 40+20 mg, more preferably 40 ⁇ 18 mg, still more preferably 40 ⁇ 15 mg, yet more preferably 40 ⁇ 13 mg, most preferably 40 ⁇ 10 mg, and in particular 40 ⁇ 8 mg.
  • the pharmaceutical dosage form contains meloxicam as the second pharmacologically active ingredient in a dose within the range of 2 mg to 28 mg, more preferably in the range of 4 mg to 26 mg, even more preferably in the range of 5 mg to 24 mg, still more preferably in the range of 6 mg to 22 mg, most preferably in the range of 7 mg to 20 mg and in particular in the range of 8 mg to 18 mg.
  • the pharmaceutical dosage form contains piroxicam as the second pharmacologically active ingredient in a dose within the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
  • the pharmaceutical dosage form contains tenoxicam as the second pharmacologically active ingredient in a dose within the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
  • the pharmaceutical dosage form contains lornoxicam as the second pharmacologically active ingredient in a dose within the range of 2 mg to 26 mg, more preferably in the range of 4 mg to 24 mg, even more preferably in the range of 5 mg to 22 mg, still more preferably in the range of 6 mg to 20 mg, most preferably in the range of 7 mg to 18 mg and in particular in the range of 8 mg to 16 mg.
  • the dose of the first pharmacologically active ingredient is preferably within the range of from 1 : 20 to 20 : 1 of the amount which is equieffective to the dosage of the second pharmacologically active ingredient.
  • "equieffective" preferably means the dosage that would be required in order to achieve the equivalent desired therapeutic effect when being administered alone.
  • the equieffective dosage is determined with respect to the analgesic properties of the first pharmacologically active ingredient and the second pharmacological ingredient.
  • the dose of the second pharmacologically active ingredient, which is contained in the pharmaceutical dosage form according to the invention amounts to e.g.
  • the dosage of the first pharmacologically active ingredient which is contained in the pharmaceutical dosage form according to the invention, may vary from 0.2 pg (4 pg/20) to 80 pg (20-4 pg).
  • the dose of the first pharmacologically active ingredient is within the range of from 1 : 15 to 15 : 1 , preferably within the range of from 1 : 10 to 10 : 1 , more preferably within the range of from 1 : 8 to 8 : 1 , still more preferably within the range of from 1 : 6 to 6 : 1 , yet more preferably within the range of from 1 : 4 to 4 : 1 , most preferably within the range of from 1 : 3 to 3 : 1 , and in particular preferably within the range of from 1 : 2 to 2 : 1 , of the amount which is equieffective to the dose of the second pharmacologically active ingredient.
  • Suitable pathways of administration of the pharmaceutical dosage form according to the invention include but are not limited to oral, intravenous, intraperitoneal, intradermal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, local and/or rectal administration.
  • the pharmaceutical dosage form according to the invention is for oral administration.
  • the pharmaceutical dosage form according to the invention is for parenteral, in particular intravenous, intraperitoneal, intrathecal, intramuscular or subcutaneous administration.
  • the pharmaceutical dosage form according to the invention is for rectal administration.
  • the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, can be solid, semi-solid or liquid.
  • the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, may contain auxiliary agents, for example, carriers, fillers, solvents, diluents, colorants and/or binders.
  • auxiliary agents for example, carriers, fillers, solvents, diluents, colorants and/or binders.
  • the selection of auxiliary agents and of the amounts of the same to be used depends, for example, on how the first and the second pharmacologically acrive ingredient are to be administered, e.g. orally, intravenously, intraperitoneally, intradermal ⁇ , transdermal ⁇ , intrathecal ⁇ , intramuscularly, intranasally, transmucosally, subcutaneously, rectally or locally.
  • Suitable auxiliary agents are in particular any substances known to a person skilled in the art useful for the preparation of galenical dosage forms.
  • suitable auxiliary agents include but are not limited to: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, saccharose, dextrose, molasses, starch, modified starch, gelatine, sorbitol, inositol, mannitol, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, cellulose acetate, shellac, cetyl alcohol, polyvinyl pyrrolidone, paraffins, waxes, natural and synthetic gums, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glycerol stearate, sodium lauryl sulphate
  • Pharmaceutical dosage forms which are suitable for oral administration include but are not limited to tablets, effervescent tablets, chewing tablets, dragees, capsules, drops, juices and syrups.
  • Oral pharmaceutical dosage forms may also be in the form of multiparticulates such as granules, pellets, spheres, crystals and the like, optionally compressed into a tablet, filled into a capsule, filled into a sachet or suspended in a suitable liquid medium.
  • Oral pharmaceutical dosage forms may also be equipped with an enteric coating.
  • compositions suitable for parenteral, topical and inhalative administration include but are not limited to solutions, suspensions, easily reconstitutable dry preparations and sprays.
  • Suppositories are a suitable pharmaceutical dosage form for rectal administration.
  • Dosage forms in a deposit, in dissolved form, for example, in a patch optionally with the addition of agents to promote skin penetration, are examples of suitable dosage forms for percutaneous administration.
  • the pharmaceutical dosage form according to the invention is a tablet.
  • the pharmaceutical dosage form according to the invention is for administration six times daily, five times daily, four times daily, thrice daily, twice daily, once daily, or less frequently.
  • the pharmaceutical dosage form according to the invention is adapted for administration less frequently than once daily, preferably thrice during four days (3/4), twice during three days (2/3), thrice during five days (3/5), once during two days (1/2), thrice in a week (3/7), twice during five days (2/5), once during three days (1/3), twice in a week (2/7), once during four days (1/4), once during five days (1/5), once during six days (1/6), or once in a week (1/7).
  • administration once during two days (1/2) is particularly preferred.
  • the pharmaceutical dosage form according to the invention is for administration less frequently than once daily, in particular once during two days (1/2).
  • the pharmaceutical dosage form according to the invention is for administration once daily.
  • the pharmaceutical dosage form according to the invention is for administration twice daily.
  • the pharmaceutical dosage form according to the invention is for administration thrice daily.
  • the pharmaceutical dosage form according to the invention is for administration multiple daily, in particular twice daily.
  • administration thrice daily preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of three pharmaceutical dosage forms per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 3 hours, preferably at least 4 hours, more preferably not least 6 hours and in particular, about 8 hours.
  • administration twice daily preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of two pharmaceutical dosage forms per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 6 hours, preferably at least 8 hours, more preferably at least 10 hours and in particular, about 12 hours.
  • administration once daily preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of one pharmaceutical dosage form per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 18 hours, preferably at least 20 hours, more preferably at least 22 hours and in particular, about 24 hours.
  • administration regimens may be realized by administering a single pharmaceutical dosage form containing the full amount of the first pharmacologically active ingredient and the full amount of the second pharmacologically active ingredient to be administered at a particular point in time or, alternatively, administering a multitude of dose units, i.e. two, three or more dose units, the sum of which multitude of dose units containing the full amount of the first pharmacologically active ingredient and the second pharmacologically active ingredient to be administered at said particular point in time, where the individual dose units are adapted for simultaneous administration or administration within a short period of time, e.g. within 5, 10 or 15 minutes.
  • the doses of the first and the second pharmacologically active ingredient are expressed according to the number of prescribed administrations "n" per day, i.e. the number of administrations of the pharmaceutical dosage form according to the invention in the course of 24 hours.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
  • the pharmaceutical dosage form according to the invention may provide under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient.
  • In vitro release is preferably determined in accordance with Ph. Eur., preferably paddle method with sinker, 75 rpm, 37 °C, 900 mL artificial gastric juice, pH 6.8.
  • the first pharmacologically active ingredient and/or the second pharmacologically active ingredient may independently of one another be present in the pharmaceutical dosage form at least partially in controlled-release form.
  • the first pharmacologically active ingredient and/or the second pharmacologically active ingredient may be released from the pharmaceutical dosage form in a prolonged manner, e.g. if administered orally, rectally or percutaneously.
  • Such pharmaceutical dosage forms are particularly useful for "once-daily" or “twice-daily" preparations, which only have to be taken once a day, respectively, twice a day.
  • Suitable controlled-release materials are well known to those skilled in the art.
  • the pharmaceutical dosage form according to the invention providing controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient may be produced using materials, means, devices and processes that are well known in the prior art of pharmaceutical dosage forms.
  • the pharmacologically active ingredients of the pharmaceutical composition may be granulated with a pharmaceutical carrier, for example conventional tablet ingredients such as corn starch, lactose, saccharose, sorbitol, talcum, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable gums, and pharmaceutical diluents, for example water, in order to form a solid composition that contains the pharmacologically active ingredients in homogeneous distribution.
  • a pharmaceutical carrier for example conventional tablet ingredients such as corn starch, lactose, saccharose, sorbitol, talcum, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable gums, and pharmaceutical diluents, for example water
  • a pharmaceutical carrier for example conventional tablet ingredients such as corn starch, lactose, saccharose, sorbitol, talcum, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable gums, and pharmaceutical diluents, for example water
  • homogeneous distribution is taken
  • pharmaceutical dosage forms having a corresponding release profile may be prepared.
  • An example of such a pharmaceutical dosage form is an osmotically-driven release system for achieving a delayed release of either the first or the second pharmacologically active ingredient from an inner part (core) of the pharmaceutical dosage form via a coating that itself contains the other pharmacologically active ingredient which is accordingly released earlier.
  • a release system of this kind which is particularly suitable for oral administration, at least part, and preferably all, of the surface of the release system, preferably those parts that will come into contact with the release medium, is/are semipermeable, preferably equipped with a semipermeable coating, so the surface(s) is/are permeable to the release medium, but substantially, preferably entirely, impermeable to the pharmacologically active ingredient contained in the core, the surface(s) and/or optionally the coating comprising at least one opening for releasing the pharmacologically active ingredient contained in the core.
  • precisely that/those surface(s) that is/are in contact with the release medium is/are provided with a coating containing and releasing the other pharmacologically active ingredient.
  • This is preferably taken to mean a system in tablet form comprising a release opening, a core containing the first or the second pharmacologically active ingredient, a polymer portion that exerts pressure upon swelling, a semipermeable membrane and a coating containing the other pharmacologically active ingredient.
  • osmotically-driven release systems are, for example, disclosed in US patents 4,765,989, 4,783,337 and 4,612,008.
  • a further example of a suitable pharmaceutical dosage form is a gel-matrix tablet.
  • Suitable examples are provided in US patents 4,389,393, 5,330,761 , 5,399,362, 5,472,711 and 5,455,046.
  • Particularly suitable is a retarding matrix dosage form, with an inhomogeneous distribution of the pharmaceutical composition, whereby, for example, one pharmacologically active ingredient, i.e. the first or the second pharmacologically active ingredient, is distributed in the outer region (the portion that comes into contact with the release medium most quickly) of the matrix and the other pharmacologically active ingredient is distributed inside the matrix.
  • the outer matrix layer On contact with the release medium, the outer matrix layer initially (and rapidly) swells and firstly releases the pharmacologically active ingredient contained therein, followed by the significantly (more) controlled release of the other pharmacologically active ingredient.
  • a suitable matrix include matrices with 1 to 80 % by weight of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers.
  • the pharmaceutical dosage form according to the invention provides immediate release of the first pharmacologically active ingredient, and immediate or controlled release of the second pharmacologically active ingredient.
  • the pharmaceutical dosage form according to the invention provides immediate release of both, the first and the second pharmacologically active ingredient.
  • the pharmaceutical dosage form according to the invention provides immediate release of the first pharmacologically active ingredient, and controlled release of the second pharmacologically active ingredient.
  • This release profile may be realized by employing the aforementioned methods, e.g. the osmotically-driven release system providing the first pharmacologically active ingredient in the coating and the second pharmacologically active ingredient in the core, or the retarding matrix dosage form containing the first pharmacologically active ingredient in the outer matrix layer and the second pharmacologically active ingredient in the inside of the matrix.
  • the pharmaceutical dosage form according to the invention provides controlled release of both the first and the second pharmacologically active ingredient.
  • the invention relates to the use of the pharmaceutical composition according to the invention, and the pharmaceutical dosage form according to the invention respectively, in the prevention or treatment of pain.
  • the pharmaceutical composition according to the invention and the pharmaceutical dosage form according to the invention, respectively, are for use in the treatment of pain, wherein the pain is preferably
  • neuropathic or psychogenic or nociceptive or mixed pain and/or - low back pain, visceral pain or headache; and/or
  • post-operative post-surgical
  • cancer post-operative cancer
  • inflammatory pain post-operative pain
  • acute pain preferably refers to pain that lasts up to about 4 weeks
  • subacute pain preferably refers to pain that lasts from more than about 4 weeks to about 12 weeks
  • chronic pain preferably refers to pain that lasts for more than about 12 weeks.
  • the pain is selected from the group consisting of cancer pain, peripheral neuropathic pain, osteoarthritis, chronic visceral pain, neuropathic pain (diabetic polyneuropathy, HIV-associated neuropathic pain, posttraumatic neuropathic pain, postherpetic neuralgia, chemotherapy associated pain), postzosteric neuralgia, postoperative neuropathic pain, inflammatory pain, migraine, low-back pain, fibromyalgia and trigeminal neuralgia.
  • neuropathic pain diabetic polyneuropathy, HIV-associated neuropathic pain, posttraumatic neuropathic pain, postherpetic neuralgia, chemotherapy associated pain
  • postzosteric neuralgia postoperative neuropathic pain
  • inflammatory pain migraine, low-back pain, fibromyalgia and trigeminal neuralgia.
  • the pain is chronic pain, in particular chronic nociceptive and/or chronic inflammatory pain.
  • the pain is non-chronic or acute pain, in particular postoperative (post-surgical) pain.
  • the pain is selected from acute or non-chronic postoperative neuropathic pain and chronic inflammatory pain.
  • the doses of the first and the second pharmacologically active ingredient are again expressed according to the number of administrations "n" per day, i.e. the number of administrations of the pharmaceutical dosage form according to the invention in the course of 24 hours.
  • the pharmaceutical dosage form is for use in the treatment of neuropathic pain which may be optionally superimposed by nociceptive pain
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n [ig or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg.
  • the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2/n mg to 50/n mg.
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n ig or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 28 mg, more preferably in the range of 4 mg to 26 mg, even more preferably
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 26 mg, more preferably in the range of 4 mg to 24 mg, even more
  • the pharmaceutical dosage form is for use in the treatment of nociceptive pain which may be optionally superimposed by neuropathic pain
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 , 400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg.
  • the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2/n mg to 50/n
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 , 400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 28 mg, more
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg,
  • the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 26
  • the pharmaceutical composition contains the first and the second pharmacologically active ingredient in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient.
  • the term "synergistic therapeutic effect” refers to a synergistic therapeutic effect with respect to the prevention or treatment of pain (synergistic analgesic effect).
  • Suitable weight ratios of the pharmacologically active ingredients generating the synergistic therapeutic effect can be determined by methods well known to those skilled in the art.
  • a further aspect of the invention relates to a method of treating or preventing pain comprising the preferably twice daily or once daily, preferably oral administration of the pharmaceutical dosage form according to the invention to a subject in need thereof.
  • the first pharmacologically active ingredient is (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl- 4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine according to formula (I) in form of its free base, or a hemicitrate, hydrochloride or maleate salt thereof; and/or
  • the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam and the physiologically acceptable salts thereof; and/or
  • the pharmaceutical composition and the pharmaceutical dosage form respectively, contain the first pharmacologically active ingredient in a dose of from 20 pg to 80 pg or of from 80 Mg to 200 pg or of from 200 pg to 800 pg or of from 800 pg to 1 ,200 pg; and/or
  • the pharmaceutical composition and the pharmaceutical dosage form respectively, contain the second pharmacologically active ingredient in a dose of from 2 mg to 50 mg; and/or
  • the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, preferably 1 : 2 to 1 : 10,000 in the pharmaceutical composition and the pharmaceutical dosage form, respectively; and/or
  • the pharmaceutical composition is for use in the prevention or treatment of pain;
  • the pharmaceutical composition is for use in the treatment of pain, wherein the pain isperipheral, central or muscle skeletal pain; and/or acute, subacute or chronic pain; and/or moderate to severe pain; and/or neuropathic or psychogenic or nociceptive or mixed pain; and/or low back pain, visceral pain or headache; and/or post-operative (post-surgical), cancer or inflammatory pain; and/or
  • the pharmaceutical composition and the pharmaceutical dosage form respectively, contain the first pharmacologically active ingredient and the second pharmacologically active ingredient in such a weight ratio that upon administration to a patient they will exert a synergistic therapeutic effect;
  • the pharmaceutical dosage form provides immediate release of the first pharmacologically active ingredient in vitro in accordance with Ph. Eur.; and/or
  • the pharmaceutical dosage form provides immediate or controlled release of the second pharmacologically active ingredient in vitro in accordance with Ph. Eur.; and/or
  • the pharmaceutical dosage form is for oral administration;
  • the pharmaceutical dosage form is for administration less frequently than once daily, in particular once during two days, or for once, twice or thrice daily.
  • the invention relates to a kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as described above, and a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as described above.
  • a suitable embodiment is a kit in which the first pharmaceutical dosage from comprising the first pharmacologically active ingredient and the second pharmaceutical dosage form comprising the second pharmacologically active ingredient, although spatially separated, are provided in a common presentation form, e.g. packaging.
  • the first and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, wherein the first pharmaceutical dosage form may be administered before or after the second pharmaceutical dosage form and wherein the first and the second pharmaceutical dosage form are administered either via the same or a different pathway of administration.
  • the term “simultaneous administration” preferably refers to an administration of the first and the second pharmaceutical dosage form within a time span of 15 minutes from each other, whereas the term “sequential administration” preferably refers to an administration of the first and the second pharmaceutical dosage form within a time span of more than 15 minutes from each other.
  • the first and the second pharmaceutical dosage form are adapted for administration to the patient via the same pathway.
  • the first and the second pharmaceutical dosage form are adapted for administration to the patient via different pathways.
  • the first and the second pharmaceutical dosage form are administered simultaneously.
  • the first and the second pharmaceutical dosage form are administered sequentially.
  • the first and/or the second pharmaceutical dosage form are adapted for administration less frequently than once daily.
  • the first and/or the second pharmaceutical dosage form are adapted for once daily administration.
  • the first and/or the second pharmaceutical dosage form are adapted for multiple daily administration, in particular twice daily or thrice daily.
  • the first pharmaceutical dosage form is adapted for once daily administration and the second pharmaceutical dosage form is adapted for multiple daily, in particular twice daily or thrice daily, administration.
  • the first pharmaceutical dosage form is adapted for multiple daily, in particular twice daily, administration and the second pharmaceutical dosage form is adapted for once daily administration.
  • Suitable pathways of administration of the pharmaceutical dosage forms contained in the kit include but are not limited to oral, intravenous, intraperitoneal, intradermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, and/or rectal administration.
  • one or both of the pharmaceutical dosage forms contained in the the kit are for oral administration.
  • one or both of the pharmaceutical dosage forms contained in the kit are for parenteral, in particular intravenous, intraperitoneal, intrathecal, intramuscular or subcutaneous administration.
  • one or both of the pharmaceutical dosage forms contained in the kit are for rectal administration.
  • the first and the second pharmaceutical dosage form are for oral, simultaneous administration less frequently than daily, in particular once during two days.
  • the first and the second pharmaceutical dosage form are for oral, simultaneous administration once daily.
  • the first and the second pharmaceutical dosage form are for oral, simultaneous administration multiple daily, twice daily or thrice daily.
  • the first and the second pharmaceutical dosage form are each for oral, sequential administration once daily.
  • first and the second pharmaceutical dosage form are for sequential administration once daily each, where the first and the second pharmaceutical dosage form are adapted for administration via different pathways, e.g. oral and parenteral or rectal administration.
  • first and the second pharmaceutical dosage form are each for oral, sequential administration less frequently than daily, in particular once during two days.
  • the first and the second pharmaceutical dosage form are each for oral, sequential administration multiple daily, in particular twice daily or thrice daily.
  • first and the second pharmaceutical dosage form are for sequential administration multiple daily each, in particular twice daily or thrice daily, where the first and the second pharmaceutical dosage form are adapted for administration via different pathways, e.g. oral and parenteral or rectal administration.
  • the first pharmacologically active ingredient (1r,4r)-6'-fluoro-N,N-dimethyl-4- phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine was employed in form of the hemicitrate salt. Therefore, all amounts of the first pharmacologically active ingredient are specified with respect to the hemicitrate salt.
  • meloxicam As the second pharmacologically active ingredient, meloxicam was employed.
  • the rats were placed in a plastic cage with a wire mesh bottom which allowed full access to the paws.
  • Hind paw withdrawal threshold after mechanical stimulation was tested with electronic von Frey hairs (Somedic Sales AB, Horby, Sweden). Animals were placed in a plastic cage with a wire mesh bottom which allowed full access to the paws. Behavioral accommodation was allowed for 30 min. In each case, withdrawal response was measured at an area adjacent to the wound (ipsilateral) and to the same area on the non-injured foot (contralateral).
  • Two hours after surgery primary hypersensitivity was tested as tactile withdrawal threshold shortly before drug administration and at different time points after drug application. Animals injected with vehicle served as controls. The pretest measurement was made prior to surgery and two thresholds were taken per test and averaged.
  • the first pharmacologically active ingredient was dissolved in 5% DMSO and 95% glucose solution (5%).
  • the second pharmacologically active ingredient was dissolved in 1% CMC in aqua dest.
  • Intravenous applications (i.v.) and intraperitoneal (i.p.) applications were made in a volume of 5 mL/kg.
  • the median values of the individual latencies are calculated as the percentage of the Maximum Possible Effect (%MPE) according to the following formula:
  • %MPE 100 - [(value after application - pretest before surgery) /
  • the individual %MPE values were averaged for the respective treatment group and expressed as mean %MPE ⁇ standard error of the mean (SEM).
  • the pharmacologically active ingredients were administered using a logarithmically staggered dose scheme. The results are presented in graphs as means ⁇ SEM against the time after surgery.
  • ED 50 values were determined by regression analysis in case of dose-dependent results (according to Litchfield J.T. and Wilcoxon F.A., A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 1949; 96: 99-113).
  • the analysis of the results with respect to a supra-additive effect of the first and the second pharmacologically active ingredient according to the invention is carried out via statistical comparison of the theoretical additive ED 50 -value or by comparison of the theoretically additive effect of defined doses of the first and the second pharmacologically active ingredient with the experimental determined effect of their combination.
  • the application route was intravenous (i.v.) for the first pharmacologically active ingredient and intraperitoneal (i.p.) for the second pharmacologically active ingredient.
  • Tests were performed using doses of 0.0046 mg/kg body weight to 0.010 mg/kg body weight of the first pharmacologically active ingredient and a dose of 21.5 mg/kg body weight of the second pharmacologically active ingredient.
  • the first and the second pharmacologically active ingredient were administered at the same time.
  • the time point of efficacy-calculation in case of the combined administration of the first and the second pharmacologically active ingredient according to the invention corresponds to the timepoint of the peak effect of the respective pharmacologically active ingredient.
  • the effect of the experiments with fixed dose combinations showed higher experimental determined efficacy than the theoretically calculated efficacy.
  • the combination studies demonstrate significant synergistic interaction of the first pharmacologically active ingredient with the second pharmacologically active ingredient.
  • the first and the second pharmacologically active ingredient When administered as a combination, the first and the second pharmacologically active ingredient showed a dose dependent analgesic efficacy.
  • a dose ratio of 1 : 2,150 combined administration of the first pharmacologically active ingredient (0.010 mg/kg body weight i.v.) and the second pharmacologically active ingredient (21.5 mg/kg body weight i.p.) resulted in a maximal effect of 82 % MPE at 30 min. after administration.
  • the analysis showed significant synergistic interaction of the first pharmacologically active ingredient (0.010 mg/kg body weight i.v.) and the second pharmacologically active ingredient (21.5 mg/kg body weight i.p.) with an ED 50 -value of 21.506 (21.506 - 21.507) mg/kg i.p./i.v.
  • Figure 1 shows the withdrawal threshold in g in dependence of the time elapsed after administration. dose [mg/kg]
  • Figure 2 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration.
  • dose [mg/kg]
  • Figure 3 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration.
  • dose [mg/kg]
  • Figure 4 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration.
  • dose [mg/kg]
  • % MPE Maximum possible effect of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
  • % MPE GLM Repeated Measures and Statistical evaluation of the data following two-factor analysis of variance (ANOVA) and Fisher's LSD:
  • % MPE Maximum possible effect of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
  • % MPE Maximum possible effect of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
  • % MPE Maximum possible effect of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
  • active ingredient p level of statistical significance.
  • the weight ratios of the first and the second pharmacologically active ingredient that will lead to a supra-additive effect may be determined via the test of Randall and Selitto as described in Arch. Int. Pharmacodyn., 1957, 111 : 409-419, which is a model for inflammatory pain.
  • the respective part of the literature is hereby incorporated by reference and forms part of the present disclosure.
  • ED 50 values were determined by regression analysis in case of dose-dependent results (according to Litchfield J.T. and Wilcoxon F.A., A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 1949; 96: 99-113).
  • the analysis of the results with respect to a supra-additive effect of the first and the second pharmacologically active ingredient is carried out via statistical comparison of the theoretical additive ED 50 -value with the experimentally determined ED 50 -value of a so-called fixed ratio combination (isobolographic analysis according to Tallarida J.T., Porreca F., and Cowan A., Statistical analysis of drug-drug and site-site interactions with isobolograms, Life Sci.
  • the application route was intravenous (i.v.) for the first pharmacologically active ingredient and intraperitoneal (i.p.) for the second pharmacologically active ingredient.
  • the first pharmacologically active ingredient was dissolved in 5% DMSO, 5% Cremophor and 90% glucose solution (5%).
  • the second pharmacologically active ingredient was dissolved in 1% CMC in aqua dest.
  • Intraveneous (i.v.) and intraperitoneal (i.p.) applications were made in a volume of 5 ml/kg.
  • the relative dose ratio of first pharmacologically active ingredient to the second pharmacologically active ingredient was 1 : 42,549.
  • the second pharmacologically active ingredient meloxicam induced a dose-dependent analgesic effect with ED 50 -values of 140,862 (1 8,952 - 166,964) pg/kg i.p., reaching the peak effect 180 min p. appl. According to their respective timepoint of peak effect, the first pharmacologically active ingredient was applied 15 min and the second pharmacologically active ingredient 180 min before timepoint of measurement of the interaction-experiments (i. e. the second pharmacologically active ingredient was applied 165 min before the first pharmacologically active ingredient).
  • the time point of ED 50 calculation in case of the combined administration of the first and the second pharmacologically active ingredient according to the invention corresponds to the timepoint of the peak effect of the respective pharmacologically active ingredient.
  • the isobolographic analysis revealed that the experimental ED 50 -values regarding the combined administration of the first and the second pharmacologically active ingredient were significantly lower than the respective theoretical ED 50 -values.
  • the combination studies demonstrate significant synergistic interaction of the first pharmacologically active ingredient with the second pharmacologically active ingredient.
  • the results of the isobolographic analysis are summarized in the following table 8.
  • Figure 5 shows the graphical analysis of experimental ED 50 -values corresponding to the single administration of the first pharmacologically active ingredient and meloxicam as the second pharmacologically active ingredient, respectively, and the corresponding theoretic additive values for the combined administration of the first and the second pharmacologically active ingredient compared to the experimental ED 50 -values determined for said combination.
  • second pharmacologically active ingredient 140,862 (118,952 - 166,964) theoretical additive value 70,437 (64,045 - 76,829) part of first pharmacologically active ingredient 1.66 (1.51 - 1.81)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.

Description

Pharmaceutical composition comprising (1 r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'- dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro- 3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
(1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano- [3,4,b]indol]-4-amine and its corresponding physiologically acceptable salts as well as methods for their preparation are well known, for example, from WO2004/043967 and WO2008/040481. The compounds exhibit analgesic properties and are particularly suitable for the treatment of acute, visceral, neuropathic or chronic (nociceptive) pain.
Oxicams are enolic acids which may preferably be regarded as NSAIDs, i.e. non-steroidal anti-inflammatory and antirheumatic drugs, which have anti-inflammatory, analgesic and antipyretic activity.
Though both of the aforementioned substance classes can be used for prevention and treatment of pain and are as such therapeutically effective, side effects may occur, especially upon prolonged use or when administered at high dosages.
It is further known that specific combinations of pharmacologically active compounds exert supra-additive (synergistic) therapeutic effects upon administration. An advantage of these special cases is that the overall dose and accordingly the risk of undesired side effects may be reduced.
In a further aspect, two pharmacologically active compounds exerting a synergistic effect may be combined in one single pharmaceutical dosage form, e.g. a tablet, thus enhancing patient compliance.
It is an object of the invention to provide pharmaceutical compositions which have advantages compared to pharmaceutical compositions of the prior art. In particular, the pharmaceutical compositions should provide rapid therapeutic effects, but also should have a high tolerability, good compliance and safety.
This object has been achieved by the subject-matter of the patent claims.
It has been surprisingly found that a pharmaceutical composition comprising (1r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine and an oxicam is useful for the treatment of pain, especially chronic inflammatory pain, or acute or non-chronic postoperative (postsurgical) pain.
Further it has been surprisingly found that said composition exhibits a synergistic therapeutic effect upon administration. Therefore, the overall administered dose may be lowered, so that fewer undesired side-effects will occur.
A first aspect of the invention relates to a pharmaceutical composition comprising: a) a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N- dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 , 1 '-pyrano[3,4,b]indol]-4- amine and the physiologically acceptable salts thereof, and b) a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
The pharmaceutical composition according to the invention comprises a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl- 4',9'-dihydro-3'l-l-spiro[cyclohexane-1 >1 '-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof.
For the purpose of specification, (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l- spiro[cyclohexane-1 ,1'-pyrano [3,4,b]indol]-4-amine is the compound according to formula (I) which can also be referred to as 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro- 1 ,3,4,9-tetrahydropyrano[3,4-b]indole (trans)
Figure imgf000004_0001
(I)
The definition of the first pharmacologically active ingredient includes (1r,4r)-6'-fluoro-N,N- dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 , 1 '-pyrano-[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I), in any possible form including solvates, cocrystals and polymorphs, and its physiologically acceptable salts, in particular acid addition salts and corresponding solvates, cocrystals and polymorphs.
The pharmacologically active ingredient (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro- 3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine may be present in the pharmaceutical composition according to the invention in form of a physiologically acceptable salt, preferably an acid addition salt, whereby any suitable acid capable of forming such an addition salt may be used.
The conversion of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclo- hexane-1 ,1'-pyrano[3,4,b]indol]-4-amine into a corresponding addition salt, for example, via reaction with a suitable acid may be effected in a manner well known to those skilled in the art. Suitable acids include but are not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid. Salt formation is preferably effected in a solvent, for example, diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or 2-butanone. Moreover, trimethylchlorosilane in aqueous solution is also suitable for the preparation of hydrochlorides.
In a preferred embodiment, the first pharmacologically active ingredient is (1 r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I).
In another preferred embodiment, the first pharmacologically active ingredient is (1 r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4- amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt.
Unless explicitly stated otherwise, all amounts of the first pharmacologically active ingredient specified in the following are given according to the corresponding amount of (1r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4- amine in form of the free base, i.e. the compound according to formula (I).
The pharmaceutical composition according to the invention comprises a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
Meloxicam, piroxicam, tenoxicam, lornoxicam and droxicam are the compounds according to formulas (II), (III), (IV), (V) and (VI), respectively.
Figure imgf000005_0001
The definition of the second pharmacologically active ingredient includes the aforementioned oxicams in any possible form including any enantiomers, if applicable, solvates, prodrugs, cocrystals and polymorphs, and their physiologically acceptable salts, in particular metal and ammonium salts and corresponding solvates, cocrystals and polymorphs.
Although the preferred oxicams according to any of formulas (II) to (VI) are devoid of an acid functionality as such, they bear acidic protons since they exhibit a keto-enol tautomerism. Additionally, they may contain nitrogen functionalities. Thus, the conversion into a salt may be effected in a manner well known to those skilled in the art, for example, via reaction with a suitable base, but as well with an acid or metal salt. Suitable bases include but are not limited to inorganic bases, including the hydroxides of sodium, potassium, calcium and/or magnesium, and organic bases, such as triethyl amine, trimethylamine, N,N-diisopropyl- ethylamine, N-methylmorpholine, N-methylpiperidine and ammonia. Suitable acids include but are not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid. Moreover, trimethylchlorosilane in aqueous solution is also suitable for the preparation of hydrochlorides. Suitable metal salts include but are not limited to alkali salts such as sodium, potassium or lithium phosphate, sulfate, methanesulfonate, formate, acetate, oxalate, succinate, tartrate, mandelate, fumarate, lactate, citrate, glutamate, aspartate and/or silyls, as well as alkaline earth salts, in particular magnesium and calcium salts, including their phosphate, sulfate, methanesulfonate, formate, acetate, oxalate, succinate, tartrate, mandelate, fumarate, lactate, citrate, glutamate, aspartate and/or silyl salts. Salt formation is preferably effected in a solvent, for example, diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or 2- butanone.
As prodrugs of the preferred oxicams according to any of formulas (II) to (VI), ethers and esters are especially preferred. Suitable methods for selecting and preparing a prodrug of a given substance are, for example, described in "Textbook of Drug Design and Discovery", 3rd edition, 2002, chapter 14, pages 410-458, Editors: Krogsgaard-Larsen et al., Taylor and Francis.
The second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof. In a preferred embodiment, the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam and the physiologically acceptable salts thereof.
Unless explicitly stated otherwise, all amounts of the second pharmacologically active ingredient specified in the following are given according to the corresponding amount of the free compound, i.e. according to any of formulas (II) to (VI).
In a preferred embodiment, the second pharmacologically active ingredient is an oxicam in form of the free compound, i.e. according to any of formulas (II) to (VI).
In another preferred embodiment, the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the free compound, i.e. according to any of formulas (II) to (V).
In still another preferred embodiment, the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the respective sodium salt.
In a preferred embodiment, the second pharmacologically active ingredient is meloxicam.
In a preferred embodiment, the first pharmacologically active ingredient is (1r,4r)-6'-fluoro- N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam according to any of formulas (II) to (VI).
In another preferred embodiment, the first pharmacologically active ingredient is (1r,4r)-6 - fluoro-N.N-dimethyl^-phenyl^'^'-dihydro-S'H-spirofcyclohexane-I '-pyranoIS^.blindolH- amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam according to any of formulas (II) to (V).
In still another preferred embodiment, the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]- 4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam and lornoxicam in form of the respective sodium salt. In yet another preferred embodiment, the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]- 4-amine in form of the free base, i.e. the compound according to formula (I), and the second pharmacologically active ingredient is meloxicam according to formula (II).
In a further preferred embodiment, the first pharmacologically active ingredient is (1r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4- amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt, and the second pharmacologically active ingredient is meloxicam according to formula (II).
In still a further preferred embodiment, the first pharmacologically active ingredient is (1r,4r)- 6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]- 4-amine in form of a physiologically acceptable acid addition salt, in particular the hydrochloride, hemicitrate or maleate salt, and the second pharmacologically active ingredient is meloxicam in form of the sodium salt.
Since the second pharmacologically active ingredient bears an acidic proton due to a keto- enol tautomerism, it may react with the first pharmacologically active ingredient according to formula (I) forming a salt which incorporates both pharmacologically active ingredients.
Thus, in another preferred embodiment, the pharmaceutical composition according to the invention comprises the first and the second pharmacologically active ingredient in form of a salt formed from these two pharmacologically active ingredients. Such a salt formation may be partial, i.e. the pharmaceutical composition according to the invention comprises one or both of these pharmacologically active ingredients also in their non-salt form, or the salt formation may essentially be complete.
Another aspect of the invention relates to a pharmaceutical dosage form comprising the pharmaceutical composition according to the invention.
The first and the second pharmacologically active ingredient are typically contained in the pharmaceutical dosage form according to the invention in a therapeutically effective amount. The amount that constitutes a therapeutically effective amount varies according to the pharmacologically active ingredients, the condition being treated, the severity of said condition, the patient being treated, and whether the pharmaceutical dosage form is designed for an immediate or controlled release.
In a preferred embodiment, the content of the first pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at most 10 wt.-% or at most 5 wt.-% or at most 3 wt.-% or at most 1.0 wt.-%, more preferably at most 0.8 wt.-%, yet more preferably at most 0.5 wt.-%, still more preferably at most 0.2 wt.-%, even more preferably at most 0.1 wt.-%, most preferably at most 0.05 wt.-%, and in particular at most 0.01 wt.-% or at most 0.005 wt- % or at most 0.001 wt.-%.
In a preferred embodiment, the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at most 95 wt.-%, more preferably at most 80 wt.-%, yet more preferably at most 70 wt.-%, still more preferably at most 60 wt.-%, even more preferably at most 55 wt.-%, most preferably at most 50 wt.-%, and in particular at most 45 wt.-%.
In another preferred embodiment, the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at most 45 wt.-%, more preferably at most 30 wt.-%, yet more preferably at most 20 wt.-%, still more preferably at most 15 wt.-%, even more preferably at most 10 wt.-%, most preferably at most 5 wt.-%, and in particular at most 1 wt.-%.
In a preferred embodiment, the content of the first pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at least 0.0001 wt.-%, more preferably at least 0.0003 wt.-%, yet more preferably at least 0.0005 wt.-%, still more preferably at least 0.0008 wt.-%, even more preferably at least 0.001 wt.-%, most preferably at least 0.003 wt.-%, and in particular at least 0.005 wt.-%.
In a preferred embodiment, the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at least 0.1 wt.-%, more preferably at least 0.5 wt.-%, yet more preferably at least 1 wt.-%, still more preferably at least 3 wt.-%, even more preferably at least 5 wt.-%, most preferably at least 7.5 wt.-%, and in particular at least 10 wt.-%.
In another preferred embodiment, the content of the second pharmacologically active ingredient in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, is at least 0.01 wt.-%, more preferably at least 0.02 wt.-%, yet more preferably at least 0.04 wt.-%, yet more preferably at least 0.06 wt.-%, most preferably at least 0.08 wt.-%, and in particular at least 0.1 wt.-%.
Unless explicitly stated otherwise, in the meaning of the invention the indication "wt.-%" shall mean weight of the respective ingredient per total weight of the pharmaceutical dosage form or per total weight of the pharmaceutical composition, respectively.
Preferably, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, more preferably 1 : 2 to 1 : 10,000, and most preferably 1 : 5 to 1 : 5,000.
In a preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 100, more preferably 1 : 4 to 1 : 90, still more preferably 1 : 6 to 1 : 80, most preferably 1 : 7 to 1 : 70, and in particular 1 : 10 to 1 : 60.
In another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 20 to 1 : 200, more preferably 1 : 30 to 1 : 185, still more preferably 1 : 50 to 1 : 170, yet more preferably 1 : 60 to 1 : 160, most preferably 1 : 70 to 1 : 140, and in particular 1 : 80 to 1 : 120.
In yet another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 100 to 1 : 900, more preferably 1 : 250 to 1 : 800, still more preferably 1 : 300 to 1 : 700, most preferably 1 : 350 to 1 : 650, and in particular 1 : 400 to 1 : 600.
In still another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 500 to 1 : 5,000, more preferably 1 : 600 to 1 : 4,000, still more preferably 1 : 700 to 1 : 3,000, most preferably 1 : 750 to 1 : 2,500, and in particular : 800 to 1 : 2,000.
In a further preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 1 ,000 to 1 : 9,000, more preferably 1 : 2,500 to 1 : 8,000, still more preferably 1 : 3,000 to 1 : 7,000, most preferably 1 : 3,500 to 1 : 6,500, and in particular 1 : 4,000 to 1 : 6,000.
In yet a further preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 3,000 to 1 : 10,000, more preferably 1 : 4,000 to 1 : 9,800, still more preferably 1 : 5,000 to 1 : 9,600, most preferably 1 : 6,000 to 1 : 9,500, and in particular 1 : 7,000 to 1 : 9,000.
Preferably, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, more preferably 1 : 2 to 1 : 10,000, and most preferably 1 : 5 to 1 : 5,000.
In a preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 100, more preferably 1 : 4 to 1 : 90, still more preferably 1 : 6 to 1 : 80, most preferably 1 : 7 to 1 : 70, and in particular 1 : 10 to 1 : 60. In another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 20 to 1 : 200, more preferably 1 : 30 to 1 : 185, still more preferably 1 : 50 to 1 : 170, yet more preferably 1 : 60 to 1 : 160, most preferably 1 : 70 to 1 : 140, and in particular 1 : 80 to 1 : 120.
In yet another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 100 to 1 : 900, more preferably 1 : 250 to 1 : 800, still more preferably 1 : 300 to 1 : 700, most preferably 1 : 350 to 1 : 650, and in particular 1 : 400 to 1 : 600.
In still another preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 500 to 1 : 5,000, more preferably 1 : 600 to 1 : 4,000, still more preferably 1 : 700 to 1 : 3,000, most preferably 1 : 750 to 1 : 2,500, and in particular 1 : 800 to 1 : 2,000.
In a further preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 1 ,000 to 1 : 9,000, more preferably 1 : 2,500 to 1 : 8,000, still more preferably 1 : 3,000 to 1 : 7,000, most preferably 1 : 3,500 to 1 : 6,500, and in particular 1 : 4,000 to 1 : 6,000.
In yet a further preferred embodiment, in the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, the relative molar ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 3,000 to 1 : 10,000, more preferably 1 : 4,000 to 1 : 9,800, still more preferably 1 : 5,000 to 1 : 9,600, most preferably 1 : 6,000 to 1 : 9,500, and in particular 1 : 7,000 to 1 : 9,000.
The amounts of the first and the second pharmacologically active ingredient contained in the pharmaceutical dosage form according to the invention may vary depending on different factors well known to those skilled in the art, for example, the weight of the patient, the route of administration, the severity of the illness and the like.
In general, both pharmacologically active ingredients contained in the pharmaceutical dosage form according to the invention may be administered in amounts up to their maximum daily dose, which is known to those skilled in the art. For example, as the second pharmacologically active ingredient, meloxicam may preferably be administered to a patient in a maximum daily dose of up to 15 mg, piroxicam may preferably be administered to a patient in a maximum daily dose of up to 40 mg, tenoxicam may preferably be administered to a patient in a maximum daily dose of up to 40 mg and lornoxicam may preferably be administered to a patient in a maximum daily dose of up to 16 mg.
When administered in the prescribed manner, e.g. once daily or twice daily, the pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, preferably contain the first and the second pharmacologically active ingredient, independently of one another, in an amount corresponding to 75±15 wt.-%, 75±10 wt.-%, 75±5 wt.-%, 50±15 wt.-%, 50±10 wt.-%, 50±5 wt.-%, 25± 5 wt.-%, 25±10 wt.-% or 25±5 wt.-% of the respective maximum daily dose of the first and the second pharmacologically active ingredient, respectively.
Preferably, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose of from 0.1 pg to 5,000 pg, more preferably, 0.1 pg to 2,500 pg, still more preferably 1.0 pg to 1 ,000 pg, yet more preferably 10 to 800 pg, most preferably 15 pg to 600 pg, and in particular 20 pg to 440 pg.
In a preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 13±12 pg, more preferably 13±10 pg, still more preferably 13±8 pg, yet more preferably 13±6 pg, even more preferably 13±5 pg, most preferably 13±4 pg, and in particular 13±3 pg.
In another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 20±15 pg, more preferably 20±13 pg, still more preferably 20±12 pg, yet more preferably 20±10 pg, even more preferably 20±8 pg, most preferably 20±6 pg, and in particular 20±5 pg. In still another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 40±35 pg, more preferably 40±30 pg, still more preferably 40±25 pg, yet more preferably 40±20 g, even more preferably 40±15 μg, most preferably 40±10 pg, and in particular 40±5 M9-
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 60+50 pg, more preferably 60±40 pg, still more preferably 60±30 pg, yet more preferably 60±20 pg, most preferably 60±10 pg, and in particular 60±5 pg.
In a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 80±70 pg, more preferably 80±60 pg, still more preferably 80±50 pg, yet more preferably 80±40 pg, even more preferably 80±20 pg, most preferably 80±10 pg, and in particular 80±5 M9-
In still a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 100±90 pg, more preferably 100±80 pg, still more preferably 100±60 pg, yet more preferably 100±40 pg, even more preferably 100±20 pg, most preferably 100±10 pg, and in particular 100±5 pg.
In yet a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 120±100 pg, more preferably 120±80 pg, still more preferably 120±60 pg, yet more preferably 120±40 pg, even more preferably 120±20 pg, most preferably 120±10 pg, and in particular 120±5 pg.
In another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 150±90 pg, more preferably 150±80 pg, still more preferably 150±60 pg, yet more preferably 150±40 pg, even more preferably 150±20 pg, most preferably 150±10 pg, and in particular 150±5 pg.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 170±130 pg, more preferably 170±100 pg, still more preferably 170+80 pg, yet more preferably 170±60 pg, even more preferably 170±40 pg, most preferably 170±20 pg, and in particular 170±10 pg.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 200±175 pg, more preferably 200±150 pg, still more preferably 200±125 pg, yet more preferably 200±100 pg, even more preferably 200+75 pg, most preferably 200±50 pg, and in particular 200±25 pg.
In a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 400±350 pg, more preferably 400±300 pg, still more preferably 400±250 pg, yet more preferably 400±200 pg, even more preferably 400±150 pg, most preferably 400±100 pg, and in particular 400±50 pg.
In another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 600±400 pg, more preferably 600±300 pg, still more preferably 600±250 pg, yet more preferably 600±200 pg, even more preferably 600±150 pg, most preferably 600±100 pg, and in particular 600±50 pg.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 800±550 pg, more preferably 800+400 pg, still more preferably 800±350 pg, yet more preferably 800±250 pg, even more preferably 800±150 pg, most preferably 800±100 pg, and in particular 800±50 pg.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 1 ,000±800 pg, more preferably 1 ,000±600 pg, still more preferably 1 ,000±500 pg, yet more preferably 1 ,000±300 pg, even more preferably 1 ,000±200 pg, most preferably 1 ,000±100 pg, and in particular 1 ,000±50 pg.
In a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the first pharmacologically active ingredient in a dose within the range of 1 ,200±1 ,000 pg, more preferably 1 ,200±800 pg, still more preferably 1 ,200±600 pg, yet more preferably 1 ,200±400 [ig, even more preferably 1 ,200±200 pg, most preferably 1 ,200±100 ig, and in particular 1 ,200±50 [ig.
Preferably, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose of from 1 mg to 75 mg, more preferably, 2 mg to 60 mg, still more preferably 5 mg to 50 mg, most preferably 8 mg to 40 mg, and in particular 10 mg to 30 mg.
In a preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 10±8 mg, more preferably 10±6 mg, most preferably 10±4 mg, and in particular 10±2 mg.
In another preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 15±10 mg, more preferably 15±8 mg, still more preferably 15±6 mg, most preferably 15±4 mg, and in particular 15±2 mg.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 20±15 mg, more preferably 20±14 mg, still more preferably 20±12 mg, yet more preferably 20±10 mg, most preferably 20±8 mg, and in particular 20±5 mg.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 25±15 mg, more preferably 25±14 mg, still more preferably 25±13 mg, yet more preferably 25±12 mg, most preferably 25±10 mg, and in particular 25±7 mg.
In a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 30±20 mg, more preferably 30±18 mg, still more preferably 30±15 mg, yet more preferably 30±13 mg, most preferably 30±10 mg, and in particular 30±8 mg.
In still a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 35±20 mg, more preferably 35±18 mg, still more preferably 35±15 mg, yet more preferably 35±13 mg, most preferably 35±10 mg, and in particular 35±8 mg. In yet a further preferred embodiment, the pharmaceutical dosage form according to the invention contains the second pharmacologically active ingredient in a dose within the range of 40+20 mg, more preferably 40±18 mg, still more preferably 40±15 mg, yet more preferably 40±13 mg, most preferably 40±10 mg, and in particular 40±8 mg.
In a preferred embodiment, the pharmaceutical dosage form contains meloxicam as the second pharmacologically active ingredient in a dose within the range of 2 mg to 28 mg, more preferably in the range of 4 mg to 26 mg, even more preferably in the range of 5 mg to 24 mg, still more preferably in the range of 6 mg to 22 mg, most preferably in the range of 7 mg to 20 mg and in particular in the range of 8 mg to 18 mg.
In another preferred embodiment, the pharmaceutical dosage form contains piroxicam as the second pharmacologically active ingredient in a dose within the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In still another preferred embodiment, the pharmaceutical dosage form contains tenoxicam as the second pharmacologically active ingredient in a dose within the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In yet another preferred embodiment, the pharmaceutical dosage form contains lornoxicam as the second pharmacologically active ingredient in a dose within the range of 2 mg to 26 mg, more preferably in the range of 4 mg to 24 mg, even more preferably in the range of 5 mg to 22 mg, still more preferably in the range of 6 mg to 20 mg, most preferably in the range of 7 mg to 18 mg and in particular in the range of 8 mg to 16 mg.
In the pharmaceutical dosage form according to the invention, the dose of the first pharmacologically active ingredient is preferably within the range of from 1 : 20 to 20 : 1 of the amount which is equieffective to the dosage of the second pharmacologically active ingredient. In this regard, "equieffective" preferably means the dosage that would be required in order to achieve the equivalent desired therapeutic effect when being administered alone. A skilled person recognizes that when the desired therapeutic effect is an analgesic effect, the equieffective dosage is determined with respect to the analgesic properties of the first pharmacologically active ingredient and the second pharmacological ingredient. For example, when the dose of the second pharmacologically active ingredient, which is contained in the pharmaceutical dosage form according to the invention, amounts to e.g. 30 mg and provides an analgesic effect E when being administered alone at this dose, and when the equieffective amount of the first pharmacologically active ingredient, i.e. the amount needed in order to provide the same analgesic effect E when being administered alone, would be e.g. 4 g, the dosage of the first pharmacologically active ingredient, which is contained in the pharmaceutical dosage form according to the invention, may vary from 0.2 pg (4 pg/20) to 80 pg (20-4 pg).
In a preferred embodiment, the dose of the first pharmacologically active ingredient is within the range of from 1 : 15 to 15 : 1 , preferably within the range of from 1 : 10 to 10 : 1 , more preferably within the range of from 1 : 8 to 8 : 1 , still more preferably within the range of from 1 : 6 to 6 : 1 , yet more preferably within the range of from 1 : 4 to 4 : 1 , most preferably within the range of from 1 : 3 to 3 : 1 , and in particular preferably within the range of from 1 : 2 to 2 : 1 , of the amount which is equieffective to the dose of the second pharmacologically active ingredient.
Suitable pathways of administration of the pharmaceutical dosage form according to the invention include but are not limited to oral, intravenous, intraperitoneal, intradermal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, local and/or rectal administration.
In a preferred embodiment, the pharmaceutical dosage form according to the invention is for oral administration.
In another preferred embodiment, the pharmaceutical dosage form according to the invention is for parenteral, in particular intravenous, intraperitoneal, intrathecal, intramuscular or subcutaneous administration.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention is for rectal administration.
The pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, can be solid, semi-solid or liquid. The pharmaceutical dosage form according to the invention and the pharmaceutical composition according to the invention, respectively, may contain auxiliary agents, for example, carriers, fillers, solvents, diluents, colorants and/or binders. The selection of auxiliary agents and of the amounts of the same to be used depends, for example, on how the first and the second pharmacologically acrive ingredient are to be administered, e.g. orally, intravenously, intraperitoneally, intradermal^, transdermal^, intrathecal^, intramuscularly, intranasally, transmucosally, subcutaneously, rectally or locally.
Suitable auxiliary agents are in particular any substances known to a person skilled in the art useful for the preparation of galenical dosage forms. Examples of suitable auxiliary agents include but are not limited to: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, saccharose, dextrose, molasses, starch, modified starch, gelatine, sorbitol, inositol, mannitol, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, cellulose acetate, shellac, cetyl alcohol, polyvinyl pyrrolidone, paraffins, waxes, natural and synthetic gums, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glycerol stearate, sodium lauryl sulphate, edible oils, sesame oil, coconut oil, peanut oil, soybean oil, lecithin, sodium lactate, polyoxyethylene and polypropylene fatty acid ester, sorbitan fatty acid ester, sorbic acid, benzoic acid, citric acid, ascorbic acid, tannic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, magnesium oxide, zinc oxide, silicon dioxide, titanium oxide, titanium dioxide, magnesium sulphate, zinc sulphate, calcium sulphate, potash, calcium phosphate, dicalcium phosphate, potassium bromide, potassium iodide, talcum, kaolin, pectin, crosspovidone, agar and bentonite.
Pharmaceutical dosage forms which are suitable for oral administration include but are not limited to tablets, effervescent tablets, chewing tablets, dragees, capsules, drops, juices and syrups. Oral pharmaceutical dosage forms may also be in the form of multiparticulates such as granules, pellets, spheres, crystals and the like, optionally compressed into a tablet, filled into a capsule, filled into a sachet or suspended in a suitable liquid medium. Oral pharmaceutical dosage forms may also be equipped with an enteric coating.
Pharmaceutical dosage forms that are suitable for parenteral, topical and inhalative administration include but are not limited to solutions, suspensions, easily reconstitutable dry preparations and sprays.
Suppositories are a suitable pharmaceutical dosage form for rectal administration. Dosage forms in a deposit, in dissolved form, for example, in a patch optionally with the addition of agents to promote skin penetration, are examples of suitable dosage forms for percutaneous administration.
In an especially preferred embodiment, the pharmaceutical dosage form according to the invention is a tablet.
In a preferred embodiment, the pharmaceutical dosage form according to the invention is for administration six times daily, five times daily, four times daily, thrice daily, twice daily, once daily, or less frequently.
In another preferred embodiment, the pharmaceutical dosage form according to the invention is adapted for administration less frequently than once daily, preferably thrice during four days (3/4), twice during three days (2/3), thrice during five days (3/5), once during two days (1/2), thrice in a week (3/7), twice during five days (2/5), once during three days (1/3), twice in a week (2/7), once during four days (1/4), once during five days (1/5), once during six days (1/6), or once in a week (1/7). According to this embodiment, administration once during two days (1/2) is particularly preferred.
In a preferred embodiment, particularly when the second pharmacologically active ingredient is meloxicam, piroxicam or tenoxicam, the pharmaceutical dosage form according to the invention is for administration less frequently than once daily, in particular once during two days (1/2).
In another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration once daily.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration twice daily.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration thrice daily.
In a further preferred embodiment, particularly when the second pharmacologically active ingredient is meloxicam or lornoxicam, the pharmaceutical dosage form according to the invention is for administration multiple daily, in particular twice daily. For the purpose of specification, "administration thrice daily" (tid) preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of three pharmaceutical dosage forms per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 3 hours, preferably at least 4 hours, more preferably not least 6 hours and in particular, about 8 hours.
For the purpose of specification, "administration twice daily" (bid) preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of two pharmaceutical dosage forms per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 6 hours, preferably at least 8 hours, more preferably at least 10 hours and in particular, about 12 hours.
For the purpose of specification, "administration once daily" (sid) preferably means that the pharmaceutical dosage form according to the invention is adapted for being consecutively administered according to a regimen comprising the administration of one pharmaceutical dosage form per day, wherein the time interval between the consecutive administration of two pharmaceutical dosage forms is at least 18 hours, preferably at least 20 hours, more preferably at least 22 hours and in particular, about 24 hours.
A skilled person is fully aware that the above administration regimens may be realized by administering a single pharmaceutical dosage form containing the full amount of the first pharmacologically active ingredient and the full amount of the second pharmacologically active ingredient to be administered at a particular point in time or, alternatively, administering a multitude of dose units, i.e. two, three or more dose units, the sum of which multitude of dose units containing the full amount of the first pharmacologically active ingredient and the second pharmacologically active ingredient to be administered at said particular point in time, where the individual dose units are adapted for simultaneous administration or administration within a short period of time, e.g. within 5, 10 or 15 minutes.
In the following, the doses of the first and the second pharmacologically active ingredient are expressed according to the number of prescribed administrations "n" per day, i.e. the number of administrations of the pharmaceutical dosage form according to the invention in the course of 24 hours. As an example, 100/n pg in case of an administration once daily (n = 1) corresponds to a dose of 100 pg, and 100/n pg in case of an administration twice daily (n = 2) corresponds to a dose of 50 pg. In a preferred embodiment, the pharmaceutical dosage form according to the invention is for administration less frequently than once daily (n = 1/2, 3/5 or 2/3), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 15/n to 100/n pg, preferably 20/n to 80/n pg, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
In another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration once daily (n = 1), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 15/n to 100/n pg, preferably 20/n to 80/n pg, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
In still another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration multiple daily (n = 2, 3, 4, 5 or 6), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 15/n to 100/n pg, preferably 20/n to 80/n pg, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention is for administration less frequently than once daily (n = 1/2, 3/5 or 2/3), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 150/n to 1 , 200/n pg, preferably 200/n to 800/n pg, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
In a further preferred embodiment, the pharmaceutical dosage form according to the invention is for administration once daily (n = 1), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 150/n to 1 , 200/n pg, preferably 200/n to 800/n pg, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet. In still a further preferred embodiment, the pharmaceutical dosage form according to the invention is for administration multiple daily (n = 2, 3, 4, 5 or 6), wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of from 150/n to 1 ,000/n g, preferably 200/n to 800/n g, and the second pharmacologically active ingredient in a dose of from 2/n to 50/n mg. According to this embodiment, the pharmaceutical dosage form according to the invention is preferably for oral administration, preferably in form of a tablet.
The pharmaceutical dosage form according to the invention may provide under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient. In vitro release is preferably determined in accordance with Ph. Eur., preferably paddle method with sinker, 75 rpm, 37 °C, 900 mL artificial gastric juice, pH 6.8.
The first pharmacologically active ingredient and/or the second pharmacologically active ingredient may independently of one another be present in the pharmaceutical dosage form at least partially in controlled-release form. For example, the first pharmacologically active ingredient and/or the second pharmacologically active ingredient may be released from the pharmaceutical dosage form in a prolonged manner, e.g. if administered orally, rectally or percutaneously. Such pharmaceutical dosage forms are particularly useful for "once-daily" or "twice-daily" preparations, which only have to be taken once a day, respectively, twice a day. Suitable controlled-release materials are well known to those skilled in the art.
The pharmaceutical dosage form according to the invention providing controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient may be produced using materials, means, devices and processes that are well known in the prior art of pharmaceutical dosage forms.
In order to obtain a solid pharmaceutical dosage form such as a tablet, for example, the pharmacologically active ingredients of the pharmaceutical composition may be granulated with a pharmaceutical carrier, for example conventional tablet ingredients such as corn starch, lactose, saccharose, sorbitol, talcum, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable gums, and pharmaceutical diluents, for example water, in order to form a solid composition that contains the pharmacologically active ingredients in homogeneous distribution. The term "homogeneous distribution" is taken to mean that the pharmacologically active ingredients are distributed uniformly over the entire composition, so that said composition may easily be divided into equally effective dose units, such as tablets, pills or capsules and the like. The solid composition is then divided into dose units. The tablets or pills of the pharmaceutical composition according to the invention may also be coated or compounded in a different manner, in order to provide a dosage form with a controlled release.
If one of the pharmacologically active ingredients is to be released prior to the other pharmacologically active ingredient, for example at least 30 minutes or 1 hour beforehand, pharmaceutical dosage forms having a corresponding release profile may be prepared. An example of such a pharmaceutical dosage form is an osmotically-driven release system for achieving a delayed release of either the first or the second pharmacologically active ingredient from an inner part (core) of the pharmaceutical dosage form via a coating that itself contains the other pharmacologically active ingredient which is accordingly released earlier. In a release system of this kind, which is particularly suitable for oral administration, at least part, and preferably all, of the surface of the release system, preferably those parts that will come into contact with the release medium, is/are semipermeable, preferably equipped with a semipermeable coating, so the surface(s) is/are permeable to the release medium, but substantially, preferably entirely, impermeable to the pharmacologically active ingredient contained in the core, the surface(s) and/or optionally the coating comprising at least one opening for releasing the pharmacologically active ingredient contained in the core. Moreover, precisely that/those surface(s) that is/are in contact with the release medium is/are provided with a coating containing and releasing the other pharmacologically active ingredient. This is preferably taken to mean a system in tablet form comprising a release opening, a core containing the first or the second pharmacologically active ingredient, a polymer portion that exerts pressure upon swelling, a semipermeable membrane and a coating containing the other pharmacologically active ingredient. Embodiments and examples of osmotically-driven release systems are, for example, disclosed in US patents 4,765,989, 4,783,337 and 4,612,008.
A further example of a suitable pharmaceutical dosage form is a gel-matrix tablet. Suitable examples are provided in US patents 4,389,393, 5,330,761 , 5,399,362, 5,472,711 and 5,455,046. Particularly suitable is a retarding matrix dosage form, with an inhomogeneous distribution of the pharmaceutical composition, whereby, for example, one pharmacologically active ingredient, i.e. the first or the second pharmacologically active ingredient, is distributed in the outer region (the portion that comes into contact with the release medium most quickly) of the matrix and the other pharmacologically active ingredient is distributed inside the matrix. On contact with the release medium, the outer matrix layer initially (and rapidly) swells and firstly releases the pharmacologically active ingredient contained therein, followed by the significantly (more) controlled release of the other pharmacologically active ingredient. Examples of a suitable matrix include matrices with 1 to 80 % by weight of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers.
Preferably, the pharmaceutical dosage form according to the invention provides immediate release of the first pharmacologically active ingredient, and immediate or controlled release of the second pharmacologically active ingredient.
In a preferred embodiment, the pharmaceutical dosage form according to the invention provides immediate release of both, the first and the second pharmacologically active ingredient.
In another preferred embodiment, the pharmaceutical dosage form according to the invention provides immediate release of the first pharmacologically active ingredient, and controlled release of the second pharmacologically active ingredient. This release profile may be realized by employing the aforementioned methods, e.g. the osmotically-driven release system providing the first pharmacologically active ingredient in the coating and the second pharmacologically active ingredient in the core, or the retarding matrix dosage form containing the first pharmacologically active ingredient in the outer matrix layer and the second pharmacologically active ingredient in the inside of the matrix.
In yet another preferred embodiment, the pharmaceutical dosage form according to the invention provides controlled release of both the first and the second pharmacologically active ingredient.
In a further aspect, the invention relates to the use of the pharmaceutical composition according to the invention, and the pharmaceutical dosage form according to the invention respectively, in the prevention or treatment of pain.
In a preferred embodiment, the pharmaceutical composition according to the invention and the pharmaceutical dosage form according to the invention, respectively, are for use in the treatment of pain, wherein the pain is preferably
- peripheral, central or muscle skeletal pain; and/or
- acute, subacute or chronic pain; and/or
- moderate to severe pain; and/or
neuropathic or psychogenic or nociceptive or mixed pain; and/or - low back pain, visceral pain or headache; and/or
post-operative (post-surgical), cancer or inflammatory pain.
For the purpose of specification, "acute pain" preferably refers to pain that lasts up to about 4 weeks, "subacute pain" preferably refers to pain that lasts from more than about 4 weeks to about 12 weeks, and "chronic pain" preferably refers to pain that lasts for more than about 12 weeks.
Preferably, the pain is selected from the group consisting of cancer pain, peripheral neuropathic pain, osteoarthritis, chronic visceral pain, neuropathic pain (diabetic polyneuropathy, HIV-associated neuropathic pain, posttraumatic neuropathic pain, postherpetic neuralgia, chemotherapy associated pain), postzosteric neuralgia, postoperative neuropathic pain, inflammatory pain, migraine, low-back pain, fibromyalgia and trigeminal neuralgia.
In a preferred embodiment, the pain is chronic pain, in particular chronic nociceptive and/or chronic inflammatory pain.
In another preferred embodiment, the pain is non-chronic or acute pain, in particular postoperative (post-surgical) pain.
In still another preferred embodiment, the pain is selected from acute or non-chronic postoperative neuropathic pain and chronic inflammatory pain.
In the following, the doses of the first and the second pharmacologically active ingredient are again expressed according to the number of administrations "n" per day, i.e. the number of administrations of the pharmaceutical dosage form according to the invention in the course of 24 hours.
In a preferred embodiment, the pharmaceutical dosage form is for use in the treatment of neuropathic pain which may be optionally superimposed by nociceptive pain, where the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n [ig or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg. According to this embodiment, the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2/n mg to 50/n mg.
In a preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of neuropathic pain and the second pharmacologically active ingredient is meloxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n ig or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 28 mg, more preferably in the range of 4 mg to 26 mg, even more preferably in the range of 5 mg to 24 mg, still more preferably in the range of 6 mg to 22 mg, most preferably in the range of 7 mg to 20 mg and in particular in the range of 8 mg to 18 mg.
In another preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of neuropathic pain and the second pharmacologically active ingredient is piroxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In still another preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of neuropathic pain and the second pharmacologically active ingredient is tenoxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In yet another preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of neuropathic pain and the second pharmacologically active ingredient is lornoxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 1/n pg to 800/n pg or 1/n pg to 600/n pg or 1/n pg to 400/n pg or 1/n pg to 250/n pg, more preferably in the range of 5/n pg to 150/n pg, even more preferably in the range of 10/n pg to 100/n pg, most preferably in the range of 20/n pg to 80/n pg and in particular in the range of 30/n pg to 50/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 26 mg, more preferably in the range of 4 mg to 24 mg, even more preferably in the range of 5 mg to 22 mg, still more preferably in the range of 6 mg to 20 mg, most preferably in the range of 7 mg to 18 mg and in particular in the range of 8 mg to 16 mg.
In another preferred embodiment, the pharmaceutical dosage form is for use in the treatment of nociceptive pain which may be optionally superimposed by neuropathic pain, where the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 , 400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg. According to this embodiment, the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2/n mg to 50/n mg.
In still another preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of nociceptive pain and the second pharmacologically active ingredient is meloxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 , 400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 28 mg, more preferably in the range of 4 mg to 26 mg, even more preferably in the range of 5 mg to 24 mg, still more preferably in the range of 6 mg to 22 mg, most preferably in the range of 7 mg to 20 mg and in particular in the range of 8 mg to 18 mg.
In yet another preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of nociceptive pain and the second pharmacologically active ingredient is piroxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In a further preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of nociceptive pain and the second pharmacologically active ingredient is tenoxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 5 mg to 50 mg, more preferably in the range of 7 mg to 45 mg, even more preferably in the range of 9 mg to 40 mg, still more preferably in the range of 12 mg to 35 mg, most preferably in the range of 13 mg to 30 mg and in particular in the range of 15 mg to 25 mg.
In still a further preferred embodiment, in particular when the pharmaceutical dosage form is for use in the treatment of nociceptive pain and the second pharmacologically active ingredient is lornoxicam, the dose of the first pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 50/n pg to 2,000/n pg or 50/n pg to 1 ,400/n pg or 50/n pg to 1 ,200/n pg or 50/n pg to 1 ,000/n pg, more preferably in the range of 100/n pg to 800/n pg, still more preferably in the range of 150/n pg to 650/n pg, even more preferably in the range of 250/n pg to 550/n pg, and most preferably in the range of 350/n pg to 450/n pg; and the dose of the second pharmacologically active ingredient contained in the pharmaceutical dosage form preferably is in the range of 2 mg to 26 mg, more preferably in the range of 4 mg to 24 mg, even more preferably in the range of 5 mg to 22 mg, still more preferably in the range of 6 mg to 20 mg, most preferably in the range of 7 mg to 18 mg and in particular in the range of 8 mg to 16 mg.
Preferably, the pharmaceutical composition contains the first and the second pharmacologically active ingredient in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient. Thereby, the term "synergistic therapeutic effect" refers to a synergistic therapeutic effect with respect to the prevention or treatment of pain (synergistic analgesic effect). Suitable weight ratios of the pharmacologically active ingredients generating the synergistic therapeutic effect can be determined by methods well known to those skilled in the art.
A further aspect of the invention relates to a method of treating or preventing pain comprising the preferably twice daily or once daily, preferably oral administration of the pharmaceutical dosage form according to the invention to a subject in need thereof.
In a particular preferred embodiment,
- the first pharmacologically active ingredient is (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl- 4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano[3,4,b]indol]-4-amine according to formula (I) in form of its free base, or a hemicitrate, hydrochloride or maleate salt thereof; and/or
- the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam and the physiologically acceptable salts thereof; and/or
- the pharmaceutical composition and the pharmaceutical dosage form, respectively, contain the first pharmacologically active ingredient in a dose of from 20 pg to 80 pg or of from 80 Mg to 200 pg or of from 200 pg to 800 pg or of from 800 pg to 1 ,200 pg; and/or
- the pharmaceutical composition and the pharmaceutical dosage form, respectively, contain the second pharmacologically active ingredient in a dose of from 2 mg to 50 mg; and/or
- the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 1 ,000,000, preferably 1 : 2 to 1 : 10,000 in the pharmaceutical composition and the pharmaceutical dosage form, respectively; and/or
- the pharmaceutical composition is for use in the prevention or treatment of pain; and/or
- the pharmaceutical composition is for use in the treatment of pain, wherein the pain isperipheral, central or muscle skeletal pain; and/or acute, subacute or chronic pain; and/or moderate to severe pain; and/or neuropathic or psychogenic or nociceptive or mixed pain; and/or low back pain, visceral pain or headache; and/or post-operative (post-surgical), cancer or inflammatory pain; and/or
- the pharmaceutical composition and the pharmaceutical dosage form, respectively, contain the first pharmacologically active ingredient and the second pharmacologically active ingredient in such a weight ratio that upon administration to a patient they will exert a synergistic therapeutic effect; and/or
- the pharmaceutical dosage form provides immediate release of the first pharmacologically active ingredient in vitro in accordance with Ph. Eur.; and/or
- the pharmaceutical dosage form provides immediate or controlled release of the second pharmacologically active ingredient in vitro in accordance with Ph. Eur.; and/or
- the pharmaceutical dosage form is for oral administration; and/or
- the pharmaceutical dosage form is for administration less frequently than once daily, in particular once during two days, or for once, twice or thrice daily.
In a further aspect, the invention relates to a kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as described above, and a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as described above.
A suitable embodiment is a kit in which the first pharmaceutical dosage from comprising the first pharmacologically active ingredient and the second pharmaceutical dosage form comprising the second pharmacologically active ingredient, although spatially separated, are provided in a common presentation form, e.g. packaging.
Preferably, the first and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, wherein the first pharmaceutical dosage form may be administered before or after the second pharmaceutical dosage form and wherein the first and the second pharmaceutical dosage form are administered either via the same or a different pathway of administration.
For the purpose of specification, the term "simultaneous administration" preferably refers to an administration of the first and the second pharmaceutical dosage form within a time span of 15 minutes from each other, whereas the term "sequential administration" preferably refers to an administration of the first and the second pharmaceutical dosage form within a time span of more than 15 minutes from each other.
In a preferred embodiment, the first and the second pharmaceutical dosage form are adapted for administration to the patient via the same pathway.
In another preferred embodiment, the first and the second pharmaceutical dosage form are adapted for administration to the patient via different pathways.
In a preferred embodiment, the first and the second pharmaceutical dosage form are administered simultaneously.
In another preferred embodiment, the first and the second pharmaceutical dosage form are administered sequentially.
In a preferred embodiment, the first and/or the second pharmaceutical dosage form are adapted for administration less frequently than once daily.
In another preferred embodiment, the first and/or the second pharmaceutical dosage form are adapted for once daily administration.
In still another preferred embodiment, the first and/or the second pharmaceutical dosage form are adapted for multiple daily administration, in particular twice daily or thrice daily.
In a preferred embodiment, the first pharmaceutical dosage form is adapted for once daily administration and the second pharmaceutical dosage form is adapted for multiple daily, in particular twice daily or thrice daily, administration.
In another preferred embodiment, the first pharmaceutical dosage form is adapted for multiple daily, in particular twice daily, administration and the second pharmaceutical dosage form is adapted for once daily administration. Suitable pathways of administration of the pharmaceutical dosage forms contained in the kit include but are not limited to oral, intravenous, intraperitoneal, intradermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, and/or rectal administration.
In a preferred embodiment, one or both of the pharmaceutical dosage forms contained in the the kit are for oral administration.
In another preferred embodiment, one or both of the pharmaceutical dosage forms contained in the kit are for parenteral, in particular intravenous, intraperitoneal, intrathecal, intramuscular or subcutaneous administration.
In still another preferred embodiment, one or both of the pharmaceutical dosage forms contained in the kit are for rectal administration.
In a preferred embodiment, the first and the second pharmaceutical dosage form are for oral, simultaneous administration less frequently than daily, in particular once during two days.
In another preferred embodiment, the first and the second pharmaceutical dosage form are for oral, simultaneous administration once daily.
In still another preferred embodiment, the first and the second pharmaceutical dosage form are for oral, simultaneous administration multiple daily, twice daily or thrice daily.
In yet another preferred embodiment, the first and the second pharmaceutical dosage form are each for oral, sequential administration once daily.
In a further preferred embodiment, the first and the second pharmaceutical dosage form are for sequential administration once daily each, where the first and the second pharmaceutical dosage form are adapted for administration via different pathways, e.g. oral and parenteral or rectal administration.
In another preferred embodiment, the first and the second pharmaceutical dosage form are each for oral, sequential administration less frequently than daily, in particular once during two days. In still another preferred embodiment, the first and the second pharmaceutical dosage form are each for oral, sequential administration multiple daily, in particular twice daily or thrice daily.
In another preferred embodiment, the first and the second pharmaceutical dosage form are for sequential administration multiple daily each, in particular twice daily or thrice daily, where the first and the second pharmaceutical dosage form are adapted for administration via different pathways, e.g. oral and parenteral or rectal administration.
The following examples further illustrate the invention but are not to be construed as limiting its scope.
Pharmacological Methods
In the following, the first pharmacologically active ingredient (1r,4r)-6'-fluoro-N,N-dimethyl-4- phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine was employed in form of the hemicitrate salt. Therefore, all amounts of the first pharmacologically active ingredient are specified with respect to the hemicitrate salt.
As the second pharmacologically active ingredient, meloxicam was employed.
Example 1: Paw incision model in rats (postoperative pain)
The experiments were carried out in male albino rats (Sprague Dawley) with 170 g - 230 g body weight from a commercial breeder (Janvier; France). The animals were housed under standardized conditions: light/dark rhythm (06.00 h - 18.00 h light, 18.00 h - 06.00 h dark); room temperature 20°C - 24°C; relative air humidity 35% - 70%; 15 air changes per hour, air movement <0.2 m/sec. The animals were given tap water and a diet of standard laboratory food (Ssniff R/M-Haltung, Ssniff Spezialdiaten GmbH, Soest, Germany) ad libitum. Both were withdrawn during the test. All rats were used only once. Ten rats were used per experimental group. There were at least five days between delivery of the animals and the day of surgery.
The rats were placed in a plastic cage with a wire mesh bottom which allowed full access to the paws. Hind paw withdrawal threshold after mechanical stimulation was tested with electronic von Frey hairs (Somedic Sales AB, Horby, Sweden). Animals were placed in a plastic cage with a wire mesh bottom which allowed full access to the paws. Behavioral accommodation was allowed for 30 min. In each case, withdrawal response was measured at an area adjacent to the wound (ipsilateral) and to the same area on the non-injured foot (contralateral). Two hours after surgery, primary hypersensitivity was tested as tactile withdrawal threshold shortly before drug administration and at different time points after drug application. Animals injected with vehicle served as controls. The pretest measurement was made prior to surgery and two thresholds were taken per test and averaged.
Surgery was performed as previously described (Brennan T.J., Vandermeulen E.P., and Gebhart G.F., Characterization of a rat model of incisional pain, Pain 1996; 64:493-501). Briefly, rats were anaesthetised with isoflurane, and a 1 cm longitudinal incision was made, through skin and fascia of the plantar aspect of the foot, starting from the proximal edge of the heel and extending toward the metatarsal toes. The plantaris muscle was elevated and incised longitudinally. The muscle origin and insertion remained intact. After spreading of the muscle and haemostasis with gentle pressure, the skin was closed with two single interrupted sutures. After surgery, the rats were allowed to recover in their home cages and the animals regained consciousness within 2 to 5 minutes. In order to ensure a complete recovery from anaesthesia the baseline value of each individual animal was recorded not until 2 hours after surgery.
The first pharmacologically active ingredient was dissolved in 5% DMSO and 95% glucose solution (5%). The second pharmacologically active ingredient was dissolved in 1% CMC in aqua dest. Intravenous applications (i.v.) and intraperitoneal (i.p.) applications were made in a volume of 5 mL/kg.
Data were recorded and the median was calculated from five values of each animal and measurement.
The median values of the individual latencies are calculated as the percentage of the Maximum Possible Effect (%MPE) according to the following formula:
%MPE = 100 - [(value after application - pretest before surgery) /
(pretest after surgery - pretest before surgery) · 100]
The individual %MPE values were averaged for the respective treatment group and expressed as mean %MPE ± standard error of the mean (SEM). The pharmacologically active ingredients were administered using a logarithmically staggered dose scheme. The results are presented in graphs as means ± SEM against the time after surgery.
Data were analyzed by means of two-factor analysis of variance (ANOVA) with repeated measures. Significance of treatment-, time- or treatment x time interaction effects was analyzed by means of Wilks' Lambda statistics. In case of a significant treatment effect, pair- wise comparison was performed at the different time points effect by Fisher's least significant difference test. Results were considered statistically significant if p < 0.05.
ED50 values were determined by regression analysis in case of dose-dependent results (according to Litchfield J.T. and Wilcoxon F.A., A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 1949; 96: 99-113). The analysis of the results with respect to a supra-additive effect of the first and the second pharmacologically active ingredient according to the invention is carried out via statistical comparison of the theoretical additive ED50-value or by comparison of the theoretically additive effect of defined doses of the first and the second pharmacologically active ingredient with the experimental determined effect of their combination. If an ED50-value could be calculated, a statistical comparison of the theoretical ED50-value with the experimentally determined ED50-value of a so-called fixed ratio combination was carried out (isobolographic analysis according to Tallarida J.T., Porreca F., and Cowan A., Statistical analysis of drug-drug and site-site interactions with isobolograms, Life Sci. 1989; 45: 947-961).
The interactions studies presented herein were performed by comparison of the theoretically additive effect of defined doses of the first and the second pharmacologically active ingredient with the experimental determined effect of their combination.
The application route was intravenous (i.v.) for the first pharmacologically active ingredient and intraperitoneal (i.p.) for the second pharmacologically active ingredient.
Tests were performed using doses of 0.0046 mg/kg body weight to 0.010 mg/kg body weight of the first pharmacologically active ingredient and a dose of 21.5 mg/kg body weight of the second pharmacologically active ingredient.
The first and the second pharmacologically active ingredient were administered at the same time.
The time point of efficacy-calculation in case of the combined administration of the first and the second pharmacologically active ingredient according to the invention corresponds to the timepoint of the peak effect of the respective pharmacologically active ingredient. The effect of the experiments with fixed dose combinations showed higher experimental determined efficacy than the theoretically calculated efficacy. Thus, the combination studies demonstrate significant synergistic interaction of the first pharmacologically active ingredient with the second pharmacologically active ingredient.
When administered as a combination, the first and the second pharmacologically active ingredient showed a dose dependent analgesic efficacy. At a dose ratio of 1 : 2,150, combined administration of the first pharmacologically active ingredient (0.010 mg/kg body weight i.v.) and the second pharmacologically active ingredient (21.5 mg/kg body weight i.p.) resulted in a maximal effect of 82 % MPE at 30 min. after administration.
The analysis showed significant synergistic interaction of the first pharmacologically active ingredient (0.010 mg/kg body weight i.v.) and the second pharmacologically active ingredient (21.5 mg/kg body weight i.p.) with an ED50-value of 21.506 (21.506 - 21.507) mg/kg i.p./i.v.
Side effects (sedation) occurred upon combined administration of the first pharmacologically active ingredient at the dose of 0.010 mg/kg body weight i.v. with the second pharmacologically active ingredient at the dose of 21.5 mg/kg body weight i.p..
Figure 1 shows the withdrawal threshold in g in dependence of the time elapsed after administration. dose [mg/kg]
• 0.0 + 0.0 vehicle first pharmacologically active ingredient
+ second pharmacologically active ingredient
Figure imgf000037_0001
* p < 0.05
** p < 0.01
*** p < 0.001
ipsilateral
contralateral
OP: operation
Figure 2 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration. dose [mg/kg]
first pharmacologically active ingredient 0.0046
second pharmacologically active ingredient 21.5
combined administration of first
Figure imgf000038_0001
pharmacologically active ingredient
+ second pharmacologically active ingredient
0.0046 + 21.5
theoretical additive value of first
pharmacologically active ingredient
+ second pharmacologically active ingredient
Figure 3 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration. dose [mg/kg]
first pharmacologically active ingredient 0.0068
second pharmacologically active ingredient 21.5
combined administration of first
Figure imgf000038_0002
pharmacologically active ingredient
+ second pharmacologically active ingredient Q QQQ^ + 21 5 theoretical additive value of first
t4r pharmacologically active ingredient
+ second pharmacologically active ingredient
Figure 4 shows % MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration. dose [mg/kg]
first pharmacologically active ingredient 0.01
Figure imgf000038_0003
second pharmacologically active ingredient 21.5
combined administration of first Q.01 + 21.5
pharmacologically active ingredient + second pharmacologically active ingredient
theoretical additive value of first
pharmacologically active ingredient
+ second pharmacologically active ingredient
The results of the isobolographic analysis are summarized in the following tables 1 to 7. Table 1 : data corresponding to figure 1
% MPE (Maximum possible effect) of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
Figure imgf000039_0001
p: level of statistical significance.
Table 2: data corresponding to figure 1
% MPE : GLM Repeated Measures and Statistical evaluation of the data following two-factor analysis of variance (ANOVA) and Fisher's LSD:
GLM (General Linear Model) %MPE
treatment time interaction
F(3,36) = 79.317 F(2,72) = 39.795 F(6,72) = 9.428
p < 0.001 p < 0.001 p < 0.001
ANOVA [Fisher's LSD]
dose
30 min. 60 min. 90 min.
[mg/kg] 0.0046 + 21.5 p < 0.001 p < 0.001 p < 0.001
0.0068 + 21.5 p < 0.001 p < 0.001 p = 0.0013
0.010 + 21.5 p < 0.001 p < 0.001 p < 0.001 p: level of statistical significance. Table 3: data corresponding to figure 1 ipsilateral : GLM Repeated Measures and Statistical evaluation of the data following two- factor analysis of variance (ANOVA) and Fisher's LSD:
Figure imgf000040_0001
p: level of statistical significance. Table 4: data corresponding to figure 1 contralateral : GLM Repeated Measures and Statistical evaluation of the data following two- factor analysis of variance (ANOVA) and Fisher's LSD:
GLM (General Linear Model) contralateral
treatment time interaction
F(3,36) = 32.366 F(2,72) = 38.199 F(6,72) = 10.877
p < 0.001 p < 0.001 p < 0.001
ANOVA [Fisher's LSD]
Figure imgf000041_0001
p: level of statistical significance. Table 5: data corresponding to figure 2
% MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
Figure imgf000041_0002
p: level of statistical significance.
*: experimental value of combined administration vs. theoretical additive value of combined administration.
Table 6: data corresponding to figure 3
% MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
Figure imgf000042_0001
p: level of statistical significance.
*: experimental value of combined administration vs. theoretical additive value of combined administration.
Table 7: data corresponding to figure 4
% MPE (Maximum possible effect) of the first and the second pharmacologically active ingredient and of the combined administration of the first and the second pharmacologically active ingredient, and the theoretical % MPE of the combined administration of the first and the second pharmacologically active ingredient in dependence of the time post administration and analysis of the interaction between the first and the second pharmacologically active ingredient:
%MPE
one-sample dose 30 min. 60 min. 90 min.
t-test* [mg/kg] Mean SEM Mean SEM Mean SEM
first
pharmacologically 0.01 43.2 ± 2.61 34.1 ± 4.88 7.7 ± 2.23 p = 0.665 active ingredient
second
pharmacologically 21.5 18.0 ± 5.80 10.5 ± 1.49 2.61 ± 0.81 p = 0.0012 active ingredient first
pharmacologically 82.2 ± 4.55 71.0 ± 5.16 45.5 ± 3.32
active ingredient (theoretical (theoretical (theoretical
+ 0.01 +
additive additive additive p < 0.001 21.5
second value: 61.2 ± value: 44.6 ± value: 10.3 ±
pharmacologically 6.36) 5.10) 2.37)
active ingredient p: level of statistical significance.
* experimental value of combined administration vs. theoretical additive value of combined administration.
Example 2: Randall Selitto test in rats
The weight ratios of the first and the second pharmacologically active ingredient that will lead to a supra-additive effect (synergistic effect) may be determined via the test of Randall and Selitto as described in Arch. Int. Pharmacodyn., 1957, 111 : 409-419, which is a model for inflammatory pain. The respective part of the literature is hereby incorporated by reference and forms part of the present disclosure.
By means of injection of 0.1 ml of Carrageenin-suspension ventrally into a hind paw of a rat an oedema is induced, on which pain is generated 4 hours later by continuously increasing pressure with a stamp (2 mm tip diameter). The antinociceptive and antihyperalgesic activity of the tested pharmacologically active ingredient is determined at different points in time after administration of the pharmacologically active ingredient. The measured value to be determined and at the same time also the end point of the pain test is the pressure at which the vocalisation reaction of the rat occurs. The percentage maximum possible effect (%MPE) is calculated. The maximum pressure of the stamp is 250 g. The group size is n = 12.
ED50 values were determined by regression analysis in case of dose-dependent results (according to Litchfield J.T. and Wilcoxon F.A., A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 1949; 96: 99-113). The analysis of the results with respect to a supra-additive effect of the first and the second pharmacologically active ingredient is carried out via statistical comparison of the theoretical additive ED50-value with the experimentally determined ED50-value of a so-called fixed ratio combination (isobolographic analysis according to Tallarida J.T., Porreca F., and Cowan A., Statistical analysis of drug-drug and site-site interactions with isobolograms, Life Sci. 1989; 45: 947- 961). The interactions studies presented herein were performed using equieffective doses of the first and the second pharmacologically active ingredient, calculated from the ratio of the respective ED50 values of the first and the second pharmacologically active ingredient if administered alone.
The application route was intravenous (i.v.) for the first pharmacologically active ingredient and intraperitoneal (i.p.) for the second pharmacologically active ingredient. The first pharmacologically active ingredient was dissolved in 5% DMSO, 5% Cremophor and 90% glucose solution (5%). The second pharmacologically active ingredient was dissolved in 1% CMC in aqua dest. Intraveneous (i.v.) and intraperitoneal (i.p.) applications were made in a volume of 5 ml/kg.
In case of the combined, simultaneous administration, the relative dose ratio of first pharmacologically active ingredient to the second pharmacologically active ingredient was 1 : 42,549.
When the first pharmacologically active ingredient (1 r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl- 4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine in form of the hemicitrate salt was applied alone, the peak effect was reached 15 min p. appl. (timepoint of first measurement) corresponding to an ED50-value of 3.31 (3.06 - 3.56) pg/kg i.v.. The second pharmacologically active ingredient meloxicam induced a dose-dependent analgesic effect with ED50-values of 140,862 (1 8,952 - 166,964) pg/kg i.p., reaching the peak effect 180 min p. appl. According to their respective timepoint of peak effect, the first pharmacologically active ingredient was applied 15 min and the second pharmacologically active ingredient 180 min before timepoint of measurement of the interaction-experiments (i. e. the second pharmacologically active ingredient was applied 165 min before the first pharmacologically active ingredient).
Thus, the time point of ED50 calculation in case of the combined administration of the first and the second pharmacologically active ingredient according to the invention corresponds to the timepoint of the peak effect of the respective pharmacologically active ingredient. The isobolographic analysis revealed that the experimental ED50-values regarding the combined administration of the first and the second pharmacologically active ingredient were significantly lower than the respective theoretical ED50-values. Thus, the combination studies demonstrate significant synergistic interaction of the first pharmacologically active ingredient with the second pharmacologically active ingredient. The results of the isobolographic analysis are summarized in the following table 8.
Figure 5 shows the graphical analysis of experimental ED50-values corresponding to the single administration of the first pharmacologically active ingredient and meloxicam as the second pharmacologically active ingredient, respectively, and the corresponding theoretic additive values for the combined administration of the first and the second pharmacologically active ingredient compared to the experimental ED50-values determined for said combination.
EDso (95% Cl)[pg/kg] (i.v./i.p.) first pharmacologically active ingredient 3.31 (3.06 - 3.56)
second pharmacologically active ingredient 140,862 (118,952 - 166,964) theoretical additive value 70,437 (64,045 - 76,829) part of first pharmacologically active ingredient 1.66 (1.51 - 1.81)
part of second pharmacologically active ingredient 70,435 (64,043 - 76,827) experimental value of the combined
administration of the first and the second 48,561 (45,399 - 51 ,603) pharmacologically active ingredient
part of first pharmacologically active ingredient 1.14 (1.06 - 1.23)
part of second pharmacologically active ingredient 48,560 (40,253 - 56,868)
Experimental ED50 values of the first and the second pharmacologically active ingredient and isobolographic analysis of the interaction between the first and the second pharmacologically active ingredient:
Figure imgf000045_0001
p: level of statistical significance.

Claims

Patent claims:
1. A pharmaceutical composition comprising: a) a first pharmacologically active ingredient, which is selected from (1 r,4r)-6'- fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1 ,1 '-pyrano- [3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and b) a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
2. The pharmaceutical composition according to claim 1 , wherein the first pharmacologically active ingredient is (1 r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'- dihydro-3'H-spiro[cyclohexane-1 ,1'-pyrano[3,4,b]indol]-4-amine.
3. The pharmaceutical composition according to claim 1 or 2, wherein the second pharmacologically active ingredient is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam and the physiologically acceptable salts thereof.
4. The pharmaceutical composition according to any of the preceding claims, which contains the first and the second pharmacologically active ingredient in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient.
5. The pharmaceutical composition according to any of the preceding claims, wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1 : 2 to 1 : 10,000.
6. The pharmaceutical composition according to any of the preceding claims for use in the prevention or treatment of pain.
7. The pharmaceutical composition according to claim 6, wherein the pain is:
peripheral, central or muscle skeletal pain; and/or
acute, subacute or chronic pain; and/or
- moderate to severe pain; and/or
neuropathic or psychogenic or nociceptive or mixed pain; and/or
- low back pain, visceral pain or headache; and/or
- post-operative (post-surgical), cancer or inflammatory pain.
8. A pharmaceutical dosage form comprising the pharmaceutical composition according to any of the preceding claims.
9. The pharmaceutical dosage form according to claim 8, which contains the first pharmacologically active ingredient in a dose of from 10 to 1 ,200 \ig.
10. The pharmaceutical dosage form according to claim 8 or 9, which contains the second pharmacologically active ingredient in a dose of from 2 to 50 mg.
11. The pharmaceutical dosage form according to any of claims 8 to 10, wherein the dosage of the first pharmacologically active ingredient is within the range of from 1 :20 to 20:1 of the amount which is equieffective to the dosage of the second pharmacologically active ingredient.
12. The pharmaceutical dosage form according to any of claims 8 to 11 , which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration.
13. The pharmaceutical dosage form according to any of claims 8 to 12, which provides under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient.
14. A kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as defined in claim 1 or 2, and a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as defined in claim 1 or 3.
15. The kit according to claim 14, wherein the first and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, either by the same or a different pathway of administration.
PCT/EP2013/001469 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam WO2013170970A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
AU2013262076A AU2013262076B2 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam
JP2015511956A JP6116677B2 (en) 2012-05-18 2013-05-16 (1r, 4r) -6′-fluoro-N, N-dimethyl-4-phenyl-4 ′, 9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano [3,4, b] Indole] -4-amine and pharmaceutical composition comprising oxicam
ES13724168.3T ES2659948T3 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1R, 4R) -6'-fluor-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3, 4, b] indole] -4-amine and meloxicam
SI201330919T SI2849746T1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro(cyclohexane-1,1'-pyrano (3,4,b)indol)-4-amine and meloxicam
EP13724168.3A EP2849746B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam
EA201401265A EA026719B1 (en) 2012-05-18 2013-05-16 PHARMACEUTICAL COMPOSITION COMPRISING (1R,4R)-6'-FLUORO-N,N-DIMETHYL-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,b]INDOL]-4-AMINE AND AN MELOXICAM
CN201380025679.3A CN104302288A (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam
BR112014028569A BR112014028569A2 (en) 2012-05-18 2013-05-16 pharmaceutical composition comprising (1r, 4r) -6-fluoro-n, n-dimethyl-4,9-dihydro-3h-spiro [cyclohexane-1,1-pyran- [3,4, b] indole] -4-amine and an oxicam
RS20180128A RS56830B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam
CA2873863A CA2873863A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
LTEP13724168.3T LT2849746T (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6`-fluoro-n,n-dimethyl-4-phenyl-4`,9`-dihydro-3`h-spiro[cyclohexane-1,1`-pyrano [3,4,b]indol]-4-amine and meloxicam
NO13724168A NO2849746T3 (en) 2012-05-18 2013-05-16
MX2014012862A MX354685B (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimet hyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam.
PL13724168T PL2849746T3 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam
DK13724168.3T DK2849746T3 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3,4 , b] indole] -4-amine and meloxicam
IL235652A IL235652B (en) 2012-05-18 2014-11-12 Pharmaceutical composition comprising (1r, 4r)- 6'-fluoro- n, n-dimethyl-4- phenyl- 4', 9'-dihydro - 3'h-spiro[cyclohexane -1, 1' -pyrano[3,4,b]indol]-4 -amine and an oxicam
HK15105570.0A HK1204939A1 (en) 2012-05-18 2015-06-11 Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an oxicam (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HRP20171843TT HRP20171843T1 (en) 2012-05-18 2017-11-27 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam
CY20181100090T CY1119824T1 (en) 2012-05-18 2018-01-24 PHARMACEUTICAL COMPOSITION OF INCLUSIVE (1R, 4R) -6'-fluoro-N, N-Dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexene-1,1-1,4- , B] INDOL] -4-AMINE AND MELOXICAM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003896 2012-05-18
EP12003896.3 2012-05-18

Publications (1)

Publication Number Publication Date
WO2013170970A1 true WO2013170970A1 (en) 2013-11-21

Family

ID=48470899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/001469 WO2013170970A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam

Country Status (23)

Country Link
US (1) US9308196B2 (en)
EP (1) EP2849746B1 (en)
JP (1) JP6116677B2 (en)
CN (2) CN108451956A (en)
AU (1) AU2013262076B2 (en)
BR (1) BR112014028569A2 (en)
CA (1) CA2873863A1 (en)
CY (1) CY1119824T1 (en)
DK (1) DK2849746T3 (en)
EA (1) EA026719B1 (en)
ES (1) ES2659948T3 (en)
HK (1) HK1204939A1 (en)
HR (1) HRP20171843T1 (en)
HU (1) HUE035122T2 (en)
IL (1) IL235652B (en)
LT (1) LT2849746T (en)
MX (1) MX354685B (en)
NO (1) NO2849746T3 (en)
PL (1) PL2849746T3 (en)
PT (1) PT2849746T (en)
RS (1) RS56830B1 (en)
SI (1) SI2849746T1 (en)
WO (1) WO2013170970A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116280A1 (en) 2015-01-23 2016-07-28 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
WO2004043967A1 (en) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclic cyclohexane derivatives
WO2005066183A1 (en) * 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclic cyclohexane derivatives with affinity for the orl1-receptor
WO2008040481A1 (en) 2006-09-29 2008-04-10 Grünenthal GmbH MIXED ORL 1/μ AGONISTS FOR TREATING PAIN
CN101327193A (en) * 2008-06-20 2008-12-24 海南锦瑞制药有限公司 Lornoxicam freeze-dried injection and preparation method thereof
US7700579B2 (en) * 2002-06-17 2010-04-20 Chiesi Farmaceutici S.P.A. Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
ES2098264T3 (en) 1989-05-22 1997-05-01 Biochemical Veterinary Res DIVALENT METAL SALTS OF INDOMETACINE.
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
TR200100708T2 (en) * 1998-09-10 2001-07-23 Nycomed Danmark A/S Quick-release pharmaceutical compositions for pharmaceutical agents.
EP1219304B1 (en) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stable parenteral solution containing diclofenac salts, their preparation and use therof
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
DE10257824B4 (en) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Composition for the treatment of pain, in particular for the treatment of joint pain
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
KR20080012976A (en) 2005-06-17 2008-02-12 화이자 인코포레이티드 Alpha-(aryl- or heteroaryl-methyl)-beta-piperidino propanamide compounds as orl1-receptor antagonists
PT2012763E (en) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
CN101147735A (en) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 Pharmaceutical composition for injection and its medicine box
DE102006056458A1 (en) 2006-11-28 2008-05-29 Grünenthal GmbH Drug preparation of tramadol and acetaminophen
PL2735338T3 (en) * 2008-09-05 2019-07-31 Grünenthal GmbH Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and pregabalin or gabapentin
MX2011002117A (en) * 2008-09-05 2011-03-28 Gruenenthal Gmbh Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3- methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid.
MX354686B (en) * 2010-08-04 2018-03-15 Gruenenthal Gmbh Star Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain.
NZ604662A (en) * 2010-08-04 2014-08-29 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
RU2589831C2 (en) * 2010-08-04 2016-07-10 Грюненталь Гмбх DRUG DOSAGE FORM CONTAINING 6'-FLUORO-(N-METHYL- OR N, N-DIMETHYL-)-4-PHENYL-4', 9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1, 1'-PYRANO[3, 4, b]INDOLE]-4-AMINE

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4389393B1 (en) 1982-03-26 1985-10-22
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US7700579B2 (en) * 2002-06-17 2010-04-20 Chiesi Farmaceutici S.P.A. Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
WO2004043967A1 (en) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclic cyclohexane derivatives
US20110319440A1 (en) * 2002-11-11 2011-12-29 Gruenenthal Gmbh Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
WO2005066183A1 (en) * 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclic cyclohexane derivatives with affinity for the orl1-receptor
WO2008040481A1 (en) 2006-09-29 2008-04-10 Grünenthal GmbH MIXED ORL 1/μ AGONISTS FOR TREATING PAIN
US20080125475A1 (en) * 2006-09-29 2008-05-29 Grunenthal Gmbh Mixed ORL1/mu-agonists for the treatment of pain
CN101327193A (en) * 2008-06-20 2008-12-24 海南锦瑞制药有限公司 Lornoxicam freeze-dried injection and preparation method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Textbook of Drug Design and Discovery", 2002, TAYLOR AND FRANCIS, pages: 410 - 458
BRENNAN T.J.; VANDERMEULEN E.P.; GEBHART G.F.: "Characterization of a rat model of incisional pain", PAIN, vol. 64, 1996, pages 493 - 501
LITCHFIELD J.T.; WILCOXON F.A.: "A simplified method of evaluating dose-effect experiments", J. PHARMACOL. EXP. THER., vol. 96, 1949, pages 99 - 113
RANDALL; SELITTO, ARCH. INT. PHARMACODYN., vol. 111, 1957, pages 409 - 419
TALLARIDA J.T.; PORRECA F.; COWAN A.: "Statistical analysis of drug-drug and site-site interactions with isobolograms", LIFE SCI., vol. 45, 1989, pages 947 - 961, XP023767229, DOI: doi:10.1016/0024-3205(89)90148-3

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116280A1 (en) 2015-01-23 2016-07-28 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
US10022353B2 (en) 2015-01-23 2018-07-17 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
EP3735970A1 (en) 2015-01-23 2020-11-11 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function

Also Published As

Publication number Publication date
RS56830B1 (en) 2018-04-30
ES2659948T3 (en) 2018-03-20
IL235652B (en) 2018-08-30
CY1119824T1 (en) 2018-06-27
US9308196B2 (en) 2016-04-12
SI2849746T1 (en) 2018-02-28
HRP20171843T1 (en) 2018-01-12
MX2014012862A (en) 2015-01-19
MX354685B (en) 2018-03-15
EA026719B1 (en) 2017-05-31
AU2013262076A1 (en) 2015-01-22
EA201401265A1 (en) 2015-05-29
NO2849746T3 (en) 2018-04-14
JP2015516450A (en) 2015-06-11
BR112014028569A2 (en) 2017-06-27
LT2849746T (en) 2018-02-12
JP6116677B2 (en) 2017-04-19
CN108451956A (en) 2018-08-28
HUE035122T2 (en) 2018-05-02
CN104302288A (en) 2015-01-21
EP2849746B1 (en) 2017-11-15
HK1204939A1 (en) 2015-12-11
AU2013262076B2 (en) 2017-10-26
PT2849746T (en) 2018-02-22
IL235652A0 (en) 2015-01-29
EP2849746A1 (en) 2015-03-25
CA2873863A1 (en) 2013-11-21
DK2849746T3 (en) 2017-12-04
US20130310371A1 (en) 2013-11-21
PL2849746T3 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
US10076510B2 (en) Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
EP2849747B1 (en) Pharmaceutical composition comprising (1r,4r)-6&#39;-fluoro-n,n-dimethyl-4-phenyl-4&#39;,9&#39;-dihydro-3&#39;h-spiro[cyclohexane-1,1&#39;-pyrano [3,4,b]indol]-4-amine and a nsar
US11311504B2 (en) Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol
AU2013262076B2 (en) Pharmaceutical composition comprising (1r,4r)-6&#39;-fluoro-N,N-dimethyl-4-phenyl-4&#39;,9&#39;-dihydro-3&#39;H-spiro[cyclohexane-1,1&#39;-pyrano [3,4,b]indol]-4-amine and an oxicam
AU2013262074B2 (en) Pharmaceutical composition comprising (1r,4r)-6&#39;-fluoro-N,N-dimethyl-4-phenyl-4&#39;,9&#39;-dihydro-3&#39;H-spiro [cyclohexane-1,1&#39;-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13724168

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/012862

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 235652

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2873863

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015511956

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013724168

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201401265

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2013724168

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013262076

Country of ref document: AU

Date of ref document: 20130516

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014028569

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014028569

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141117